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A B S T R A C T
Background
Radiotherapy has been proposed as a treatment for new vessel growth in people with neovascular age-related macular degeneration
(AMD).
Objectives
To examine the eEects of radiotherapy on neovascular AMD.
Search methods
We searched CENTRAL, MEDLINE, Embase, LILACS and three trials registers and checked references of included studies. We last searched
the databases on 4 May 2020.
Selection criteria
We included all randomised controlled trials in which radiotherapy was compared to another treatment, sham treatment, low dosage
irradiation or no treatment in people with choroidal neovascularisation (CNV) secondary to AMD.
Data collection and analysis
We used standard procedures expected by Cochrane. We graded the certainty of the evidence using GRADE. We considered the following
outcomes at 12 months: best-corrected visual acuity (BCVA) (loss of 3 or more lines, change in visual acuity), contrast sensitivity, new vessel
growth, quality of life and adverse eEects at any time point.
Main results
We included 18 studies (n = 2430 people, 2432 eyes) of radiation therapy with dosages ranging from 7.5 to 24 Gy. These studies mainly took
place in Europe and North America but two studies were from Japan and one multicentre study included sites in South America. Three of
these studies investigated brachytherapy (plaque and epimacular), the rest were studies of external beam radiotherapy (EBM) including
one trial of stereotactic radiotherapy. Four studies compared radiotherapy combined with anti-vascular endothelial growth factor (anti-
VEGF) with anti-VEGF alone. Eleven studies gave no radiotherapy treatment to the control group; five studies used sham irradiation; and
one study used very low-dose irradiation (1 Gy). One study used a mixture of sham irradiation and no treatment. FiJeen studies were
judged to be at high risk of bias in one or more domains.
Radiotherapy versus no radiotherapy
There may be little or no diEerence in loss of 3 lines of vision at 12 months in eyes treated with radiotherapy compared with no radiotherapy
(risk ratio (RR) 0.82, 95% confidence interval (CI) 0.64 to 1.04, 811 eyes, 8 studies, I2 = 66%, low-certainty evidence).  Low-certainty
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evidence suggests a small benefit in change in visual acuity (mean diEerence (MD) -0.10 logMAR, 95% CI -0.17 to -0.03; eyes = 883; studies
= 10) and average contrast sensitivity at 12 months (MD 0.15 log units, 95% CI 0.05 to 0.25; eyes = 267; studies = 2). Growth of new
vessels (largely change in CNV size) was variably reported and It was not possible to produce a summary estimate of this outcome.
The studies were small with imprecise estimates and there was no consistent pattern to the study results (very low-certainty evidence).
Quality of life was only reported in one study of 199 people; there was no clear diEerence between treatment and control groups (low-
certainty evidence). Low-certainty evidence was available on adverse eEects from eight of 14 studies. Seven studies reported on radiation
retinopathy and/or neuropathy. Five of these studies reported no radiation-associated adverse eEects. One study of 88 eyes reported one
case of possible radiation retinopathy. One study of 74 eyes graded retinal abnormalities in some detail and found that 72% of participants
who had radiation compared with 71% of participants in the control group had retinal abnormalities resembling radiation retinopathy
or choroidopathy. Four studies reported cataract surgery or progression: events were generally few with no consistent evidence of any
increased occurrence in the radiation group. One study noted transient disturbance of the precorneal tear film but there was no evidence
from the other two studies that reported dry eye of any increased risk with radiation therapy. None of the participants received anti-VEGF
injections.
Radiotherapy combined with anti-VEGF versus anti-VEGF alone
People receiving radiotherapy/anti-VEGF were probably more likely to lose 3 or more lines of BCVA at 12 months compared with anti-VEGF
alone (RR 2.11, 95% CI 1.40 to 3.17, 1050 eyes, 3 studies, moderate-certainty). Most of the data for this outcome come from two studies of
epimacular brachytherapy (114 events) compared with 20 events from the one trial of EBM. Data on change in BCVA were heterogenous (I2
= 82%). Individual study results ranged from a small diEerence of -0.03 logMAR in favour of radiotherapy/anti-VEGF to a diEerence of 0.13
logMAR in favour of anti-VEGF alone (low-certainty evidence). The eEect diEered depending on how the radiotherapy was delivered (test
for interaction P = 0.0007). Epimacular brachytherapy was associated with worse visual outcomes (MD 0.10 logMAR, 95% CI 0.05 to 0.15,
820 eyes, 2 studies) compared with EBM (MD -0.03 logMAR, 95% CI -0.09 to 0.03, 252 eyes, 2 studies). None of the included studies reported
contrast sensitivity or quality of life. Growth of new vessels (largely change in CNV size) was variably reported in three studies (803 eyes). It
was not possible to produce a summary estimate and there was no consistent pattern to the study results (very low-certainty evidence). For
adverse outcomes, variable results were reported in the four studies. In three studies reports of adverse events were low and no radiation-
associated adverse events were reported. In one study of epimacular brachytherapy there was a higher proportion of ocular adverse events
(54%) compared to the anti-VEGF alone (18%). The majority of these adverse events were cataract. Overall 5% of the treatment group had
radiation device-related adverse events (17 cases); 10 of these cases were radiation retinopathy. There were diEerences in average number
of injections given between the four studies (1072 eyes). In three of the four studies, the anti-VEGF alone group on average received more
injections (moderate-certainty evidence).
Authors' conclusions
The evidence is uncertain regarding the use of radiotherapy for  neovascular AMD. Most studies took place before the routine use of
anti-VEGF,  and before the development of modern radiotherapy techniques such as stereotactic radiotherapy. Visual outcomes with
epimacular brachytherapy are likely to be worse, with an increased risk of adverse events,   probably related to vitrectomy. The role of
stereotactic radiotherapy combined with anti-VEGF is currently uncertain. Further research on radiotherapy for neovascular AMD may not
be justified until current ongoing studies have reported their results.
P L A I N   L A N G U A G E   S U M M A R Y
How e5ective is radiotherapy for treating wet age-related macular degeneration (AMD) (a degenerative eye condition)?
Why this question is important
AMD is a common condition of the eyes that may develop in people aged over 50. It aEects the central area (macula) of the back of the
eye (retina). First, yellow spots (drusen) develop under the retina. These can been seen by health professionals during examinations of the
eyes. As AMD progresses, new blood vessels can grow in the macula. These vessels may bleed or cause scarring; this is called ‘neovascular’
or ‘wet’ AMD. Wet AMD can cause people to lose the central part of their vision.
There is no cure for wet AMD. However, there are treatments designed to stop vision from worsening. One such treatment is radiotherapy
(using radiation to kill harmful cells). To find out how eEective radiotherapy is for treating wet AMD and whether it causes unwanted eEects,
we reviewed the evidence from research studies.
How we identified and assessed the evidence
First, we searched for all relevant studies in the medical literature. We then compared the results, and summarized the evidence from all
the studies. Finally, we assessed how certain the evidence was. We considered factors such as the way studies were conducted, study sizes,
and consistency of findings across studies. Based on our assessments, we categorized the evidence as being of very low-, low-, moderate-
or high-certainty.
What we found
We identified 18 relevant studies on a total of 2340 people with wet AMD. These studies mainly took place in Europe and North
America, though two studies were from Japan and one study included sites in South America. FiJeen studies investigated external beam
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radiotherapy and three studies investigated internal radiotherapy (brachytherapy), where radioactive materials are placed on the surface
of the eye.
Studies compared:
# radiotherapy alone with no radiotherapy or a sham treatment (14 studies,1223 people); or
# radiotherapy plus eye injections (of a medicine called anti-vascular endothelial growth factor (VEGF)) with eye injections only (four
studies,1117 people); or
The studies showed that:
When radiotherapy was compared with no radiotherapy or a sham treatment, at 12-month follow-up
# There may be little diEerence in how likely people’s vision is to worsen by 3 lines or more on a vision chart (low-certainty).
# There may be a small diEerence in average visual sharpness (in the order of 1 line of a vision chart) favouring radiotherapy (low-certainty).
# People’s ability to distinguish between bright and dim parts of an image may be slightly better with radiotherapy (low-certainty).
# The evidence on growth of new blood vessels in the back of the eye was inconsistent (very low-certainty).
# There may be little diEerence in quality of life (low-certainty).
# Studies that recorded unwanted eEects generally reported no radiation-associated damage to the retina or optical nerve. Other unwanted
eEects, such as cataracts, were uncommon. There was no consistent evidence that unwanted eEects were more likely in the radiation
group (low-certainty).
When radiotherapy combined with anti-VEGF was compared with anti-VEGF alone, 12 months follow-up
# People treated with radiotherapy plus anti-VEGF are probably twice as likely to lose 3 lines or more on a vision chart than people treated
with anti-VEGF alone (moderate-certainty).
# Studies reported inconsistent results on average vision sharpness (low-certainty) and new vessel growth (very low-certainty evidence).
Average vision sharpness may be worse with brachytherapy.
# No studies investigated the impact on people’s ability to distinguish between bright and dim parts of an image, or quality of life.
# Three out of four studies reported few unwanted eEects and no radiation-associated damage to the retina or optical nerve. In one study,
half of the people treated with brachytherapy reported unwanted eEects (particularly cataracts) and there were some instances of damage
to the retina caused by the brachytherapy (low-certainty).
# In three out of four studies, people treated with radiotherapy received fewer anti-VEGF injections (moderate-certainty).
Conclusion
It is uncertain whether radiotherapy on its own or with eye injections of anti-VEGF is eEective for treating wet AMD.
How up-to-date is this review?
Cochrane researchers searched for studies that had been published up to 4 May 2020. 
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Summary of findings 1.   Radiotherapy versus control for neovascular AMD
Radiotherapy versus control for neovascular AMD
Patient or population: people with neovascular AMD
Settings: eye hospital
Intervention: radiation therapy
Comparator: control (no treatment or sham irradiation) 
Anticipated absolute effects* (95% CI)Outcomes
Risk with control Risk with radiotherapy
Relative effect
(95% CI)
No of
people
or eyes
(stud-
ies)
Certain-
ty of
the evi-
dence
(GRADE)
Comments
Loss of 3 or more lines of best-
corrected visual acuity
Measured using a logMAR chart
Follow-up: 12 months
 550 per 1,000  451 per 1,000 (352 to 666) RR 0.82 (0.64 to 1.04) 811 eyes
(8 RCTs)
 ⊕⊕⊝⊝
low 1
At 24 months,
RR 0.78 (0.63
to 0.97), 654
eyes (4 RCTs)
I2 = 73%
Change in best corrected visu-
al acuity (logMAR units)
Measured using a logMAR chart.
Lower scores represent better
visual acuity
Follow-up: 12 months 
Change in visual acuity in con-
trol group ranged from -0.339
to 0.395 logMAR units.
The mean difference in visual
acuity in the intervention groups
was -0.10 logMAR units (better)
(-0.17 to -0.03)
- 883 eyes
(10 RCTs)
⊕⊕⊝⊝
low 2
At 24 months,
the mean dif-
ference in
change visual
acuity in the
radiothera-
py group was
-0.09 logMAR
units (bet-
ter) (-0.15 to
-0.03) com-
pared with
control, 516
eyes (6 RCTs)
Contrast sensitivity (log con-
trast threshold)
Measured using a Pelli-Robson
chart. Higher scores represent
better contrast sensitivity.
One trial reported change in
control group of 0.39 log units
The mean difference was
0.15 more log units (better)
(0.05 to 0.25)
  267 eyes
(2 RCTs)
⊕⊕⊝⊝
low 3
At 24 months,
MD 0.11 lo-
gunits, (0.00
to 0.22) com-
pared with
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Follow-up: 12 months control, 257
eyes (2 RCTs)
New vessel growth
Measured using fluorescein
angiography or fundus pho-
tographs
Follow-up: 12 months
It was not possible to produce a summary estimate due to variable reporting of this outcome.
The studies were small with imprecise estimates and there was no consistent pattern to the
study results.
(9 RCTs) ⊕⊝⊝⊝
very low
4
 
Quality of life
Follow-up: 12 months
Mean change in scores on four dimensions of Daily Living Tasks Dependent on Vision were sim-
ilar in radiotherapy and control groups. Mean differences ranged from -2.80 (-8.89 to 3.29) to
1.20 (-7.53 to 9.93).
199 peo-
ple
(1 RCT)
⊕⊕⊝⊝
low 5
 
Any adverse outcome
Follow-up: any time point
Six out of 14 studies did not report on adverse effects. Seven studies reported on radiation
retinopathy and/or neuropathy. Five of these studies reported no radiation-associated adverse
effects. One study of 88 eyes reported one case of possible radiation retinopathy. One study
of 74 eyes graded retinal abnormalities in some detail and found that 72% of participants who
had radiation compared with 71% of participants in the control group had retinal abnormali-
ties resembling radiation retinopathy or choroidopathy. Four studies reported cataract surgery
or progression: events were generally low and no consistent evidence of any increased occur-
rence in the radiation group. One study noted transient disturbance of the precorneal tear film
but no evidence from the other 2 studies that reported dry eye of any increased risk with radia-
tion therapy.
881 eyes
(8 RCTs)
⊕⊕⊝⊝
low 6
 
Number of anti-VEGF injec-
tions
Not relevant to this comparison - -  
*The risk with control was estimated from the pooled risk in the control groups of the included studies. The risk with radiotherapy (and its 95% confidence interval) is
based on the risk in the control group and therelative effect of the intervention (and its 95% CI).
AMD: age-related macular degeneration Anti-VEGF: anti-vascular endothelial growth factor CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate-certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low-certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low-certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1Downgraded one level for risk of bias (6 of the 8 studies were high risk of bias in one or more domain) and downgraded one level for inconsistency (individual study eEect
estimates ranged from 0.42 to 1.22, I2 = 66%).  We did not downgrade an additional level for imprecision, even though the confidence intervals include 1 (no diEerence), because
we had already downgraded for inconsistency which will have contributed to the imprecision of the pooled estimate.
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2 Downgraded one level for risk of bias (8 of the 10 studies were high risk of bias in one or more domain); and downgraded one level for publication bias as there was an asymmetric
funnel plot indicating possible publication bias.
3 Downgraded one level for risk of bias (both studies were high risk of bias in one or more domains); and downgraded one level for imprecision (the upper confidence interval
was close to 0, no diEerence).
4Downgraded one level for risk of bias (8 out of the 9 studies were high risk of bias in one or more domain); downgraded one level for imprecision (the individual studies were
small with imprecise estimates); and downgraded one level for inconsistency (there was no consistent pattern to the individual study results)
5 Downgraded one level for risk of bias study (study was not masked); and downgraded one level for imprecision (confidence intervals include 0).
6Downgraded one level for risk of bias (8 out of the 9 studies were high risk of bias in one or more domain); downgraded one level for imprecision (the individual studies were
small with imprecise estimates).
 
 
Summary of findings 2.   Radiotherapy combined with anti-VEGF versus anti-VEGF alone for neovascular AMD
Radiotherapy combined with anti-VEGF versus anti-VEGF alone for neovascular AMD
Patient or population: people with neovascular AMD
Settings: eye hospital
Intervention: radiation therapy (external beam or brachytherapy) combined with anti-VEGF (ranibizumab or bevacizumab)
Comparator: anti-VEGF alone (ranibizumab or bevacizumab) 
Anticipated absolute effects* (95% CI)Outcomes
Risk with anti-VEGF Risk with radiotherapy com-
bined with anti-VEGF
Relative effect
(95% CI)
No of
people
or eyes
(stud-
ies)
Certain-
ty of
the evi-
dence
(GRADE)
Comments
Loss of 3 or more lines of
best-corrected visual acuity
Measured using a logMAR
chart
Follow-up: 12 months
 70 per 1,000 148 per 1,000 (98 to 222) RR 2.11
(1.40 to 3.17)
1050
eyes
(3 RCTs)
 ⊕⊕⊕⊝
moder-
ate1
At 24
months,
RR 2.39
(1.68, 3.39),
820 eyes
(2 RCTs)
Change in best corrected vi-
sual acuity (logMAR units)
Measured using a logMAR
chart. Lower scores repre-
sent better visual acuity
Follow-up: 12 months 
We did not pool study results because of substantial heterogeneity. Individual study results
ranged from a small mean difference of -0.03 logMAR in favour of radiotherapy combined with an-
ti-VEGF to a mean difference of 0.13 logMAR in favour of anti-VEGF alone (I2 = 82%). There was ev-
idence of a difference in effect depending on how the radiotherapy was delivered(test for interac-
tion P=0.0007). Epimacular brachytherapy was associated with worse visual outcomes (MD 0.10
logMAR, 95% CI 0.05 to 0.15, 2 studies, 820 eyes) compared with external beam radiotherapy (MD
-0.03logMAR, 95% CI -0.09 to 0.03, 252 eyes). 
1072
eyes
(4 RCTs)
⊕⊕⊝⊝
low 2
At 24
months, the
mean dif-
ference in
change vi-
sual acu-
ity in the
radiother-
apy with
anti-VEGF
group
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was 0.17
logMAR
(worse)
(CI 0.11 to
0.23) com-
pared with
anti-VEGF
alone,
819 eyes,
2 RCTs of
epimacular
brachyther-
apy
Contrast sensitivity (log
contrast threshold)
Measured using a Pelli-Rob-
son chart. Higher scores rep-
resent better contrast sensi-
tivity.
Follow-up: 12 months
None of the included studies reported this outcome. - -  
New vessel growth
Measured using fluorescein
angiography or fundus pho-
tographs
Follow-up: 12 months
It was not possible to produce a summary estimate due to variable reporting of this outcome.
There was no consistent pattern to the individual study results.
803 eyes
(3 RCTs)
⊕⊝⊝⊝
very
low3
 
Quality of life
Follow-up: 12 months
None of the included studies reported this outcome. - -  
Any adverse outcome
Follow-up: any time point
Variable results were reported in the 4 studies. In 3 studies reports of adverse events were low and
no radiation-associated adverse events reported. In one study of epimacular brachytherapy the
radiotherapy and anti-VEGF treatment group had a higher proportion of ocular adverse events
(54%) compared to the anti-VEGF alone (18%). The majority of these adverse events were cataract.
Overall 5% of the treatment group had radiation device-related adverse events (17 cases); 10 of
these cases were radiation retinopathy.
1072
eyes
(4 RCTs)
⊕⊕⊝⊝
low 6
 
Number of anti-VEGF injec-
tions
There were some differences in average number of injections. In 3 of the 4 studies, the anti-VEGF
alone group on average received more injections
1072
eyes
(4 RCTs)
⊕⊕⊕⊝
moder-
ate1
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*The risk with control was estimated from the pooled risk in the control groups of the included studies. The risk with radiotherapy (and its 95% confidence interval) is
based on the risk in the control group and therelative effect of the intervention (and its 95% CI).
AMD: age-related macular degeneration Anti-VEGF: anti-vascular endothelial growth factor CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate-certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low-certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low-certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1Downgraded one level for risk of bias (2 of the studies were at risk of performance and detection bias).
2Downgraded one level for risk of bias (3 of the 4 studies were high risk of bias in one or more domain); and downgraded one level for inconsistency (I2 = 81%).
3Downgraded one level for risk of bias (2 of the studies were at risk of performance and detection bias); downgraded one level for imprecision (2 of the individual studies estimates
were imprecise); and downgraded one level for inconsistency (there was no consistent pattern to the individual study results).
4Downgraded one level for risk of bias (3 out of the 4 studies were high risk of bias in one or more domain); downgraded one level for inconsistency (diEerent results in the
diEerent studies).
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B A C K G R O U N D
Description of the condition
The macula, the central area of the retina, is used for detailed
vision such as reading, recognising faces and driving. Age-related
macular degeneration (AMD) is the leading cause of blindness in
higher income countries (Flaxman 2017). It is diEicult to get a
clear definition of AMD. The term 'age-related' is used partly due
to its unknown pathogenesis. It is believed that both genetic and
environmental factors play a significant role in the development of
the disease (Evans 2012). From a clinical perspective, AMD primarily
aEects the macular region. The term 'degeneration' is used to
distinguish AMD from other genetic macular dystrophies which run
in families and those where there is a clear environmental cause
such as an infection or trauma.
There are several signs appearing in the retina that are associated
with increasing age and increased risk of developing AMD. These
signs, known as age-related maculopathy (ARM), include the
presence of drusen (yellow spots beneath the retina), pigmentary
disturbance and small focal areas of atrophy. In general, ARM is not
associated with significant visual loss. Some people with ARM will
go on to develop AMD.
There are two types of AMD: geographic atrophy (large area of
atrophy centred in the macula) and choroidal neovascularisation
(CNV) also known as wet AMD. This review is concerned with
treatment for neovascular AMD.
In neovascular AMD, CNV develops beneath the retina. In the initial
phase the CNV might cause visual distortion due to leakage of
fluid into the surrounding retina. At this stage the retinal function
is only mildly aEected and the CNV is potentially reversible.
However, the CNV may leak serum lipid and protein leading to
exudation and significant swelling of the retina. The CNV may
bleed and the haemorrhages may be toxic. Both exudation and
haemorrhages induce a scarring response. These are associated
with extensive damage to the architecture of the retina-retinal
pigment epithelium-choroid complex, leading to significant visual
loss.
Choroidal neovascularisation is defined as classic or occult
according to its appearance on fluorescein angiography, where
fluorescent dye is injected intravenously and imaged as it passes
through the blood vessels of the eye. Classic membranes are
clearly delineated and can be seen in the early frames of the
angiogram. Occult membranes present as either late leakage,
which cannot be seen in the early frames, or fibrovascular pigment
epithelial detachment. Most lesions have both classic and occult
components.
Description of the intervention
Radiotherapy is commonly used in oncology and its use is
increasing in the treatment of non-neoplastic diseases. It is
believed that it can preferentially damage dividing and fast growing
cells more than normal supporting cells. In rats, photoreceptor
cell death is not seen at doses less than 10 Gy and the retinal
pigment epithelial cell loss does not occur under 20 Gy in single-
fraction. There is also evidence to suggest that fractionation of
irradiation greatly reduces the toxicity but preserves the DNA-
damaging eEects in rapidly dividing cells.
There are two ways of delivering the radiation dose, either
by external beam radiotherapy (i.e. from outside the eye) or
by brachytherapy whereby the dose is delivered intra-ocularly
or transscleral. The original external beam radiation therapy
techniques delivered high-energy radiation through the eye and
surrounding tissue. More recent modifications of this technique
include stereotactic radiotherapy whereby lower doses are applied
in a targeted fashion. In epimacular brachytherapy, aJer vitrectomy
the radiation source is applied to the fovea for a short period of
time.
How the intervention might work
Clinical experience suggests that cumulative doses of up to 25
Gy seldom cause damage to the retina or optic nerve. Radiation
therapy is anti-angiogenic. Radiation targets cells that are dividing.
As the endothelial cells in CNV are dividing the hypothesis is that
radiotherapy can stop the growth of new blood vessels without
significant damage to the retina.
Why it is important to do this review
There are several RCTs of radiotherapy for neovascular AMD using
diEerent dosage and fractionation schemes. The aim of this review
was to assess systematically the results of these studies with a view
to providing an overall estimate of treatment eEect.
O B J E C T I V E S
To examine the eEects of radiotherapy on neovascular AMD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs).
Types of participants
We included trials in which participants were people with CNV
secondary to AMD as defined by the study investigators.
Types of interventions
We included studies in which radiotherapy, no matter how it
was delivered, was compared to another treatment, low dosage
irradiation, sham treatment or no treatment.
Types of outcome measures
The outcomes have been amended for the current update: see
DiEerences between protocol and review.
Primary outcomes
The primary outcome for this review was visual acuity. We
considered two measures of visual acuity: 3 or more lines best-
corrected visual acuity (BCVA) lost on a logMAR chart (equivalent to
doubling of visual angle or worse) and change in mean BCVA as a
continuous score.
Secondary outcomes
The secondary outcomes for this review were:
• mean change in contrast sensitivity;
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• proportion of people with new vessel growth;• mean (median) quality of life measured using any validated
measurement scale which aims to measure the impact of visual
function loss on quality of life of participants;• any adverse outcomes as reported in trials.
In a protocol amendment we added the following outcome:
• number of anti-VEGF injections during the first 12 and 24
months.
Follow up
We measured outcomes at 12 (6 to 18) and 24 (18 to 30) months aJer
radiation treatment.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist conducted
systematic searches in the following databases for randomised
controlled trials and controlled clinical trials. There were no
restrictions to language or year of publication. The date of the
search was 4 May 2020.
• Cochrane Central Register of Controlled Trials (CENTRAL; 2020,
Issue 5) (which contains the Cochrane Eyes and Vision Trials
Register) in the Cochrane Library (searched 4 May 2020)
(Appendix 1).• MEDLINE Ovid (1946 to 4 May 2020) (Appendix 2).• Embase Ovid (1980 to 4 May 2020) (Appendix 3).• LILACS (Latin American and Caribbean Health Science
Information database (1982 to 4 May 2020) (Appendix 4).• International Standard Randomised Controlled Trial Number
(ISRCTN) registry (www.isrctn.com/editAdvancedSearch;
searched 4 May 2020) (Appendix 5).• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov; searched 4 May 2020)
(Appendix 6).• World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (www.who.int/ictrp; searched 22 May
2019. Update search not run as the database is not available due
to Covid 19 resource restrictions) (Appendix 7).
Searching other resources
We contacted the investigators of the trials included in this review
for information about further trials. We searched the reference lists
of relevant studies for further trial reports. We did not perform
manual searches of conference proceedings or journals.
Data collection and analysis
Selection of studies
Two review authors independently scanned the titles and abstracts
resulting from the searches. We obtained full-text copies of all
potentially or definitely relevant articles. Two review authors
assessed the full-text copies according to the 'Criteria for
considering studies for this review'. We resolved disagreements by
discussion.
Data extraction and management
Two review authors independently extracted data using a form
developed by Cochrane Eyes and Vision. We resolved discrepancies
by discussion. In the original review (Sivagnanavel 2004), one
author entered data into RevMan 4.2 using the double data-entry
facility to check for errors. For the updates in Review Manager
5 (RevMan 5) (Review Manager 2014), data were entered onto a
spreadsheet and cut and pasted into RevMan.
Assessment of risk of bias in included studies
We used Cochrane's tool for assessing risk of bias.
Selection bias
Sequence generation:• Low risk of bias: Computer generated list, random table, other
method of generating random list• Unclear risk of bias: Not reported how list was generated. Trial
may be described as “randomised” but with no further details.• High risk of bias: Alternate allocation, date of birth, records
(these RCTs should be excluded)
Allocation concealment• Low risk of bias: Central centre (web/telephone access), sealed
opaque envelopes• Unclear risk of bias: Not reported how allocation administered.
Trial may be described as “randomised” but with no further
details.• High risk of bias: Investigator involved in treatment allocation or
treatment allocation clearly not masked
Performance bias
Masking of participants and personnel• Low risk of bias: Sham treatment in control group and/or clearly
stated that participants and personnel (apart from person
applying intervention) not aware of which treatment received• Unclear risk of bias: Described as “double blind” with no
information on who was masked.• High risk of bias: No information on masking and interventions
diEerent
Detection bias• Low risk of bias: clearly stated that outcome assessors were
masked and/or sham irradiation in control group• Unclear risk of bias: Described as “double blind” with no
information on who was masked.• High risk of bias: No information on masking and interventions
diEerent
Attrition bias• Low risk of bias: Missing data less than 20% (i.e. more than 80%
follow-up) and equal follow-up in both groups and no obvious
reason why loss to follow-up should be related to outcome• Unclear risk of bias: Follow-up not reported or missing data
>20% (i.e. follow-up <80%) but follow-up equal in both groups• Follow-up diEerent in each group and/or related to outcome
Radiotherapy for neovascular age-related macular degeneration (Review)
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Selective outcome reporting• Low risk of bias: outcomes on protocol or trial registry entry
reported• Unclear risk of bias: no access to protocol or trial registry entry• High risk of bias: outcomes on protocol or trial registry entry not
reported
Measures of treatment e5ect
We used the mean diEerence (MD) with 95% confidence intervals
(CI) for continuous outcomes (e.g. visual acuity logMAR score) and
risk ratio (RR) with 95% CI for dichotomous outcomes (e.g. loss of 3
or more lines of BCVA).
Unit of analysis issues
Most studies randomised participants and then studied one eye per
person. One trial (Jaakkola 2005) reported data from 88 eyes in 86
participants. As the numbers of people with both eyes erroneously
included in the analysis was small in this study, and it was not
possible to extract data for people, this error was ignored and data
on eyes used in the analysis. There were no cross-over or cluster
RCTs, indeed they would not be expected for this intervention. Two
of the studies were three arm studies with two intervention groups
of with diEerent doses of radiotherapy. For the purposes of the
analysis, we combined the intervention groups using the RevMan
calculator.
Dealing with missing data
Our analyses assume that missing data are missing at random.
In previous versions of this review we did sensitivity analyses to
look at the eEect of missing data (Evans 2010). Under various
reasonable assumptions regarding missing data, the percentage
change in the pooled estimates was small. We have not repeated
these analyses for the current update.
Assessment of heterogeneity
We assessed heterogeneity by looking at the forest plots to
see whether the confidence intervals for the estimates of eEect
overlapped and by looking at the χ2 and I2 value.
Assessment of reporting biases
We investigated publication bias by doing a scatter plot of the eEect
estimates from the individual studies against their standard error.
We only did this on analyses that included 10 or more study results.
An asymmetric graph may indicate that smaller studies that are
not statistically significant have not been published although it also
may indicate that the eEects of treatment are diEerent in small
studies.
We assessed selective outcome reporting using the Cochrane risk
of bias tool (Assessment of risk of bias in included studies).
Data synthesis
We used a random-eEects model to combine results. When data
were sparse and we judged a random-eEects model would not
provide a robust estimate of eEect (for example, if there were three
or fewer trials), we used a fixed-eEect model.
Subgroup analysis and investigation of heterogeneity
Not all of the trials reported data for all outcomes. This meant
that our options for exploring the sources of heterogeneity were
limited. In our protocol we specified three factors of interest for
subgroup analyses (method of delivery, dosage and type of CNV).
In a previous version of this review we identified one additional
aspect of study design as being of interest for subgroup analysis.
This was whether or not sham irradiation was carried out in the
control group.
Using these factors we performed stratified analyses, the
purpose of which was to determine whether the outcome varied
significantly with type of explanatory variable. We divided the trials
into two groups for each factor:
• external beam versus brachytherapy;• high dose (more than 14 Gy) versus low dose (less than or equal
to 14 Gy);• 50% or more of participants with classic CNV versus less than
50% with classic CNV; and• trials with no sham irradiation versus those with sham
irradiation.
Sensitivity analysis
We did not conduct any sensitivity analyses.
Summary of findings and assessment of the certainty of the
evidence
We prepared a summary of findings table presenting relative
and absolute risks. One author (JE) graded the overall quality
of the evidence for each outcome using the GRADE classification
(GRADEpro) and the other authors checked this grading. We
included the following outcomes at 12 months: loss of 3 or more
lines BCVA, change in BCVA, contrast sensitivity, new vessel growth,
quality of life, any adverse outcome (any time point), and number
of anti-VEGF injections.
R E S U L T S
Description of studies
Results of the search
The searches conducted in July  2004 identified 149 reports.
A further two potentially relevant reports were identified by
subsequent electronic searching carried out for another project. We
obtained full copies of 28 reports which referred to 23 potentially
relevant studies. We excluded 12 of these trials largely because the
treatment groups were not randomly allocated. A total of 11 trials
were considered suitable for inclusion in the review (Anders 1998;
Bergink 1998; Char 1999; Ciulla 2002; Eter 2002; Kacperek 2001;
Kobayashi 2000; Marcus 2001; RAD 1999; SFRADS 2002; Valmaggia
2002).
An update  search done in March 2010 identified 487 reports of
trials. AJer initial assessment by the Trials Search Co-ordinator,
477 references were excluded as they were deemed not relevant
to the scope of the review and the review authors subsequently
assessed ten reports. Of these ten reports, three were relevant trials
(AMDLRTSG 2003; AMDRT 2004; Jaakkola 2005), six were ineligible
trials and one was a report on quality of life outcomes in SFRADS
2002.
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Update searches run in May 2020 identified a further 1120 records
(Figure 1). The Cochrane Information Specialist removed 217
duplicates and screened the remaining 903 reports, of which 804
were not relevant to the scope of the review. We reviewed the
remaining 99 reports and discarded 80 records as not relevant. We
obtained 19 full-text reports for potential inclusion in the review. We
included 11 reports of four new studies - CABERNET 2013, INTREPID
2013, MERLOT 2016 and Osmanovic 2017 - and included a further
three reports of the RAD 1999 study, which was already included in
the previous version of this review. A newly published report from
the MERLOT 2016 study giving results at 24 months was added to
this review just prior to publication of this update.
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Figure 1.   Study flow diagram.
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We excluded four studies. See Characteristics of excluded studies
for details. We identified one ongoing study and will include it in the
review when data becomes available (STAR (NCT02243878)). 
Summary
The current edition of the review has 18 included studies
(Characteristics of included studies), 22 excluded studies
(Characteristics of excluded studies) and one  ongoing
study (Characteristics of ongoing studies).
Included studies
See Table 1 and Table 2.
Types of studies
All studies were parallel group randomised controlled trials; people
were randomly allocated to treatment and one eye per person
enrolled in the trial. In three trials it was not clear how many eyes
were studied (Anders 1998; Ciulla 2002; Kacperek 2001). In Jaakkola
2005 two (out of 82) participants had both eyes enrolled.
Types of participants
The 18  trials randomised a total of 2430  people (2432 eyes).
The studies took place in Germany (Anders 1998; Eter 2002; RAD
1999), the Netherlands (Bergink 1998), Finland (Jaakkola 2005),
USA (AMDRT 2004; Char 1999; Ciulla 2002; Marcus 2001; Osmanovic
2017), Japan (AMDLRTSG 2003; Kobayashi 2000), UK (Kacperek
2001;MERLOT 2016;  SFRADS 2002), and Switzerland (Valmaggia
2002). Three studies were multi-centre: CABERNET 2013 took place
in US, Europe, Israel, South America, INTREPID 2013 took place in
Europe and MERLOT 2016 was conducted in the UK.
The average age of participants in the studies ranged from 71 to 77
years (median average age 76 years). In most studies the majority of
participants were women; the percentage female ranged from 30%
to 69% (median 60%).
Most studies recruited participants with subfoveal CNV associated
with AMD. INTREPID 2013 did not specify that the CNV had to be
subfoveal. Most studies, with the exception of AMDLRTSG 2003,
Anders 1998, INTREPID 2013 and Kacperek 2001, classified the
CNV lesion as classic, occult or mixed (Table 2).  The percentage
of participants with classic CNV ranged between 12% (Marcus
2001;MERLOT 2016) and 57% (Valmaggia 2002). The percentage of
participants with occult CNV ranged between 2% (SFRADS 2002)
and 75% (MERLOT 2016).
Two studies did not specify visual acuity criteria for entry to the
trial (Eter 2002; Valmaggia 2002). Most studies specified worst
visual acuity in the study eye, in the region of 6/60 and 6/120
(AMDLRTSG 2003; AMDRT 2004; Anders 1998; Bergink 1998; Ciulla
2002; Jaakkola 2005; Kacperek 2001; Marcus 2001; RAD 1999;
SFRADS 2002); two studies did not specify a worst acuity (Char 1999;
Kobayashi 2000). More recent trials (CABERNET 2013; INTREPID
2013;  MERLOT 2016;  Osmanovic 2017) specified more moderate
thresholds of visual impairment e.g. 6/12.
Types of intervention
Table 3 shows the detail of the radiation therapy and control in
the diEerent studies. FiJeen studies used external beam radiation
therapy. The dosages ranged from 24 Gy (Bergink 1998; INTREPID
2013; Osmanovic 2017) to 7.5 Gy (Char 1999). Three studies used
brachytherapy with a dose of 24 Gy (CABERNET 2013; MERLOT 2016)
and 12.6 Gy delivered over 11 minutes (Jaakkola 2005).
Eleven of the studies gave no radiotherapy treatment to the control
group (AMDLRTSG 2003; Anders 1998; Bergink 1998;  CABERNET
2013;  Char 1999; Eter 2002;  Jaakkola 2005; Kacperek 2001;
Kobayashi 2000; MERLOT 2016;  SFRADS 2002); five  studies
used sham irradiation (Ciulla 2002;  INTREPID 2013;  Marcus
2001; Osmanovic 2017  ; RAD 1999) and one study used very low-
dose irradiation (1 Gy) (Valmaggia 2002). In AMDRT 2004 some
participants in the control group received sham irradiation and
others received no treatment.
In the four more recent trials, radiation therapy was combined with
anti-VEGF treatment - ranibizumab (CABERNET 2013;  INTREPID
2013;  MERLOT 2016)  and either ranibizumab or bevacizumab
(Osmanovic 2017).
Types of outcome measures
In most studies the primary outcome was visual acuity. This was
usually measured using the ETDRS chart or equivalent logMAR
chart. The exception to this was Bergink 1998 where Snellen
acuity was measured. Most studies considered some aspect of
the clinical progression of CNV such as area of CNV (AMDLRTSG
2003; AMDRT 2004; Kobayashi 2000;  Osmanovic 2017;  Valmaggia
2002) and appearance of the fundus on fluorescein angiography
(Jaakkola 2005; Marcus 2001; RAD 1999). Near vision (SFRADS
2002) and reading ability (Valmaggia 2002) were also considered.
Five studies specifically considered safety (AMDRT 2004; Kobayashi
2000; MERLOT 2016; Osmanovic 2017; SFRADS 2002). In INTREPID
2013 and MERLOT 2016 the primary outcome was the number of pro
re nata (PRN) ranibizumab injections administered over 52 weeks.
Excluded studies
See 'Characteristics of excluded studies' table.
Risk of bias in included studies
Figure 2 and Figure 3 summarise the assessment of the risk of bias
in included studies.
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Figure 2.   Methodological quality graph: review authors' judgements about each methodological quality item
presented as percentages across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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AMDLRTSG 2003 ? ? - + - - ? -
AMDRT 2004 ? + - + - + - ?
Anders 1998 ? ? - + - - - ?
Bergink 1998 ? ? - + - + - -
CABERNET 2013 ? ? - ? - + + -
Char 1999 ? ? - + - + - ?
Ciulla 2002 ? ? + + + + - ?
Eter 2002 ? ? - + - + - ?
INTREPID 2013 + + + + + + + +
Jaakkola 2005 ? ? - + - + ? ?
Kacperek 2001 ? ? - + - - - ?
Kobayashi 2000 + + - + - + ? ?
Marcus 2001 + - + + + + - -
MERLOT 2016 + + - ? + + + +
Osmanovic 2017 + + + + +
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Figure 3.   (Continued)
MERLOT 2016 + + - ? + + + +
Osmanovic 2017 + - + + + + - -
RAD 1999 + + + + + + + ?
SFRADS 2002 + + - ? - ? ? +
Valmaggia 2002 ? + + + + + ? ?
 
Allocation
For five  studies,  trial reports indicated that randomisation had
been executed properly, that is, an unpredictable sequence
of treatment allocation was concealed properly from people
recruiting participants into the trial  (INTREPID 2013; Kobayashi
2000; MERLOT 2016; RAD 1999; SFRADS 2002). 
In two studies the method of generating the allocation schedule
was not clearly described but it was clear that the schedule was
concealed (AMDRT 2004; Valmaggia 2002).
In one study the allocation was almost certainly unpredictable
but it was printed out so clearly was not concealed (Marcus
2001).  In another study the allocation was almost certainly
unpredictable (coin toss) but was administered by an unmasked
study co-ordinator and balanced in a way that was probably not
random (Osmanovic 2017).
The other nine studies did not report the randomisation in suEicient
detail (AMDLRTSG 2003; Anders 1998; Bergink 1998; CABERNET
2013; Char 1999; Ciulla 2002; Eter 2002; Jaakkola 2005; Kacperek
2001).
Blinding
We judged six studies to be at low risk of performance and detection
bias for both visual acuity and lesion size (Ciulla 2002;  INTREPID
2013; Marcus 2001; Osmanovic 2017; RAD 1999; Valmaggia 2002).
All these studies gave convincing accounts of masking through
sham radiotherapy and clear statements that participants, study
personnel and outcome assessors were masked.  
There were 12 studies that did not perform sham
irradiation  (AMDLRTSG 2003; AMDRT 2004; Anders 1998; Bergink
1998; CABERNET 2013; Char 1999; Eter 2002; Jaakkola 2005;
Kacperek 2001; Kobayashi 2000; MERLOT 2016;SFRADS 2002). We
judged all these studies at high risk of performance bias for visual
acuity. We also judged them to be at high risk of detection bias for
visual acuity with the exception of   MERLOT 2016 where masked
outcome assessors were used for visual acuity measurement. 
We judged most studies to be at low risk of performance bias for
lesion size on fluorescein angiography. We judged that masking,
or lack of it, was unlikely to aEect performance bias  in studies
where other treatments were not available. There were two studies
where participants and personnel were unmasked and where the
availability of anti-VEGF treatment meant that we were unsure as
to the possibility of performance bias (CABERNET 2013; MERLOT
2016). 
We felt that masking, or lack of masking, may well aEect detection
bias for lesion size on fluorescein angiography. Three studies did
not report masking of assessment of lesion size and so were judged
to be high risk of bias (AMDLRTSG 2003; Anders 1998; Kacperek
2001). The remaining studies were judged low risk of bias as the
reports mentioned specific eEorts to mask this outcome. 
SFRADS 2002 did not report lesion size. 
Incomplete outcome data
Only four  studies were judged to be at low risk of attrition bias
i.e. they reported high rates of follow-up that were  reasonably
equal between treatment groups (CABERNET 2013; INTREPID
2013; MERLOT 2016; RAD 1999). For five studies follow-up was not
reported in enough detail to make a judgement (AMDLRTSG 2003;
Jaakkola 2005; Kobayashi 2000; SFRADS 2002; Valmaggia 2002).
The remaining studies were judged to be at high risk of attrition bias
with lower proportions lost to follow-up and/or unequal follow-up
between groups.
Selective reporting
In five studies not all the trials registry or protocol outcomes were
reported (AMDLRTSG 2003; Bergink 1998; CABERNET 2013; Marcus
2001; Osmanovic 2017). In most of the other studies, in the absence
of trials registry entries and protocols, it was unclear. In only two
studies (INTREPID 2013; SFRADS 2002) there was a trials registry
entry that also corresponded with the published reports.
Other potential sources of bias
No other potential sources of bias were noted.
E5ects of interventions
See: Summary of findings 1 Radiotherapy versus control for
neovascular AMD; Summary of findings 2 Radiotherapy combined
with anti-VEGF versus anti-VEGF alone for neovascular AMD
See Summary of findings 1.
1. Radiotherapy versus control for neovascular AMD
Fourteen studies considered this comparison:  13 studies used
external beam radiation therapy with doses ranging from 24
Gy (Bergink 1998) to 7.5 Gy (Char 1999) and one study used
plaque brachytherapy with a dose of 12.6 Gy delivered over 11
minutes (Jaakkola 2005). Nine of the studies gave no radiotherapy
treatment to the control group (AMDLRTSG 2003; Anders 1998;
Bergink 1998; Char 1999; Eter 2002;  Jaakkola 2005; Kacperek 2001;
Kobayashi 2000; SFRADS 2002), three studies used sham irradiation
(Ciulla 2002;    Marcus 2001  ;  RAD 1999), one study did a mixture
of sham irradiation and observation (AMDRT 2004), and one study
used very low-dose irradiation (1 Gy) (Valmaggia 2002).
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1.1 Loss of 3 or more lines of best-corrected visual acuity
Eight studies (811 eyes) reported data on this outcome at 12 months
(Analysis 1.1).  The results were heterogenous. Individual study
estimates ranged from 0.42 (0.26 to 0.69) in favour of radiotherapy
(Valmaggia 2002) to 1.22 (0.91 to 1.62) in favour of no radiotherapy
(Marcus 2001). The I2  value suggested that a substantial proportion
of this variation was not due to chance (I2 = 66%). The overall pooled
value was 0.82 (95% CI 0.64   to 1.04). We judged this to be low-
certainty evidence. We downgraded one level for risk of bias (6
of the 8 studies were high risk of bias in one or more domains)
and downgraded one level for inconsistency (individual study
eEect estimates ranged from 0.42 to 1.22, I2 = 66%).   We did not
downgrade an additional level for imprecision, even though the
confidence intervals include 1 (no diEerence), because we had
already downgraded for inconsistency which will have contributed
to the imprecision of the pooled estimate.
We performed subgroup analyses by dose of radiation, type of CNV
and sham irradiation in the control group (Table 4). Although there
were some diEerences between subgroups, none of the diEerences
were statistically significant (test for interaction). 
Five studies reported this outcome at 24 months (Analysis 1.2).there
was heterogeneity with study results ranging from 0.58 (0.43 to
0.80) in favour of radiotherapy (Kobayashi 2000) to 1.03 (0.79 to
1.36) (Jaakkola 2005) (I2 = 73%). The pooled risk ratio for studies of
radiotherapy compared with no radiotherapy was 0.78 (95% CI 0.63
to 0.97).
1.2 Change in best-corrected visual acuity
Ten studies (883 eyes) reported mean change in best-corrected
visual acuity or final best-corrected visual acuity at 12
months (Analysis 1.3). Study results ranged from -0.33 logMAR units
in favour of radiotherapy (Ciulla 2002) to 0.07 logMAR units in
favour of no radiotherapy (Marcus 2001) (I2 = 49%). People receiving
radiation therapy on average had a small (approximately 1 line)
better visual acuity at 12 months (mean diEerence (MD) -0.10, 95%
CI -0.17 to -0.03). These analyses may be at risk of selective outcome
bias because continuous data may be ana lysed two ways - as final
visual acuity or change in visual acuity from baseline. It is possible
that the choice of which outcome to present was influenced by the
results. We also noted an asymmetric funnel plot (Figure 4) possibly
indicative of publication bias. We judged this to be low-certainty
evidence, downgrading for risk of bias and publication bias.
 
Figure 4.
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We performed subgroup analyses by dose, type of CNV and sham
irradiation in the control group (Table 5). Although there were
some diEerences between subgroups, none of the diEerences were
statistically significant (test for interaction).
1.3 Contrast sensitivity
Two studies reported contrast sensitivity measured on a Pelli-
Robson chart (Jaakkola 2005; SFRADS 2002). There was a small
diEerence in favour of radiation therapy at 12 months (MD 0.15
logunits, 95% CI 0.05 to 0.25; eyes = 267) (Analysis 1.5) and 24
months (MD 0.11 logunits, 95% CI 0.00 to 0.22; eyes = 257). We
judged this to be low-certainty evidence downgrading one level for
risk of bias (as neither of these two studies were masked) and one
level for imprecision (confidence intervals close to 0).
Marcus 2001 reported the % contrast sensitivity threshold (Pelli-
Robson chart). At 12 months there were some diEerences in the
distribution in the treatment and observation groups but it was not
possible to exclude the possibility that these were chance findings
(P = 0.18).
 
Threshold % Radiation
 
(n = 37)
n (%)
Control
 
(n = 33)
n (%)
< 10 8 (22) 15 (45)
11 to 49 10 (27) 5 (15)
> 50 19 (51) 13 (39)
 
1.4 New vessel growth
CNV was reported in diEerent ways which makes it diEicult to
produce a summary estimate.
Size of CNV at 12 months (continuous)
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Radiation therapy ControlStudy
Mean SD n Mean SD n
Mean
differ-
ence
(95% CI)
Comments
AMDLRTSG
2003
0.082 0.738 32 0.886 0.562 22 -0.80
(-1.15 to
-0.46)
Disc diameters measured by fluorescein angiog-
raphy.
Follow-up: 12 months
Eter 2002 56 - 27 28 - 15 28.00
(-78.67
to
134.67)
(estimat-
ed using
reported
P value
of 0.61)
Average % increase in membrane size measured
by fluorescein angiography.
Follow-up: 6 months
Kobayashi
2000
8.305 9.967 45 8.172 7.674 39 0.13
(-3.65 to
3.91)
CNV area mm2 measured using the Heidelberg
Retina Tomograph
Follow-up: 12 months
Marcus 2001 1.83 - 37 1.21 - 33 0.62
(-0.17 to
1.41) (es-
timated
using re-
ported P
value of
0.13)
Increase in CNV (categories), measured using
fluorescein angiograms and colour fundus pho-
tographs.
Follow-up: 12 months
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SD: Standard deviation Size of CNV at 12 months (dichotomous)
 
Study Radiation
therapy
n/N
Control
n/N
Risk ratio (95%
CI)
Comments
Bergink
1998
7/34
(20%)
7/29
(25%)
0.81 (0.25 to
2.68)
Number of people in whom the size of the CNV doubled over 12 months
measured using fluorescein angiography
Follow-up: 12 months
Jaakkola
2005
33/43
(77%)
29/41
(71%)
1.37 (0.51 to
3.62)
CNV "less active" measured by fluorescein angiography
Follow-up: 12 months
 
Results from other studies were as follows:
• Char 1999 reported no diEerences in CNV area and membrane
edge but we were not able to extract data.• Ciulla 2002 reported that the greatest linear dimension of CNV
was not associated with treatment but data not reported.• Valmaggia 2002 CNV size increased in all groups. The authors
reported no significant  diEerences between groups but data
could not be extracted.
We judged this to be very low-certainty evidence. We downgraded
one level for risk of bias (eight out of the nine studies reporting
this outcome were high risk of bias in one or more domain);
downgraded one level for imprecision (the individual studies were
small with imprecise estimates); and downgraded one level for
inconsistency (there was no consistent pattern to the individual
study results).
1.5 Quality of life
Quality of life outcomes were reported in SFRADS 2002. Visual
functioning was assessed by the Daily Living Tasks Dependent
on Vision (DLTV) questionnaire (Hart 1999). There were no
important diEerences between treatment and control groups on
any dimension of the DLTV 12 or 24 months aJer treatment.
 
Change at 12 months
mean (standard error)
Change at 24 months
mean (standard error)
DLTV
di-
men-
sion
Radiation thera-
py
n = 87
Control
n = 86
Mean difference
(95% CI)
Radiation thera-
py
n = 87
Control
n = 88
Mean difference
(95% CI)
1 -10.6 (2.2) -9.5 (2.6) -1.10 (-7.77 to 5.57) -13.5 (2.3) -15.5 (3.3) 2.00 (-5.90 to 9.90)
2 -10.6 (2.2) -7.8 (2.2) -2.80 (-8.89 to 3.29) -10.6 (2.5) -11.9 (2.6) 1.30 (-5.77 to 8.37)
3 -8.4 (2.4) -6.5 (2.3) -1.90 (-8.41 to 4.61) -8.2 (2.4) -10.7 (1.7) 2.50 (-3.26 to 8.26)
4 -2.0 (3.1) -3.2 (3.2) 1.20 (-7.53 to 9.93) -3.2 (3.0) -3.2 (2.4) 0.00 (-7.53 to 7.53)
 
We judged this to be low-certainty evidence. We downgraded one
level for risk of bias study (study was not masked) and downgraded
one level for imprecision (confidence intervals include 0).
1.6 Adverse outcomes
Reports of adverse outcomes are described in Table 6.
Six studies did not report on adverse eEects (AMDLRTSG 2003; Char
1999; Ciulla 2002; Eter 2002; Jaakkola 2005; Kacperek 2001).
Eight studies (991 eyes) reported on adverse eEects.
Radiation-associated retinopathy or neuropathy
Seven studies reported on radiation retinopathy, neuropathy
or both. Five of these studies reported no radiation-associated
adverse eEects. One study of 88 eyes reported one case of
possible radiation retinopathy. One study of 74 eyes graded retinal
abnormalities in some detail and found that 72% of participants
who had radiation compared with 71% of participants in the control
group had retinal abnormalities resembling radiation retinopathy
or choroidopathy.
• AMDRT 2004 (88 eyes): 1 case of possible radiation retinopathy
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• Bergink 1998 (74 eyes): 72% in radiation group, 71% in control
group retinal abnormalities resembling radiation retinopathy or
choroidopathy• Kobayashi 2000 (101 eyes): reported no radiation-associated
adverse eEects• Marcus 2001 (83 eyes): reported no radiation-associated adverse
eEects• RAD 1999 (205 eyes): reported no radiation-associated adverse
eEects• SFRADS 2002 (203 eyes): reported no radiation-associated
adverse eEects• Valmaggia 2002 (161 eyes): reported no radiation-associated
adverse eEects
Cataract
Four studies reported cataract surgery or progression: events
were generally low and no consistent evidence of any increased
occurrence in the radiation group.
• AMDRT 2004 (88 eyes): cataract surgery on two participants, 1 in
each group• Kobayashi 2000 (101 eyes): cataract observed in 1 participant in
radiation group• Marcus 2001 (83 eyes): cataract progression similar in radiation
and control groups• RAD 1999 (295 eyes): cataract developed in 7 (10.3%) radiation
group, 12 (16%) control group) (P = 0.218).
Dry eye
One study noted transient disturbance of the precorneal tear film
but no evidence from the other 2 studies that reported dry eye of
any increased risk with radiation therapy.
• AMDRT 2004 (88 eyes): 2 cases of ocular dryness in radiation
group, 4 in control group• RAD 1999 (205 eyes): dry eye symptoms in were recorded in
30 (40%) radiation group and 38 (45.2%) in control group (P =
0.525).• SFRADS 2002 (203 eyes): transient disturbance of the precorneal
tear film noted in treated participants
Other• AMDRT 2004 (88 eyes): 5 deaths, 1 in radiation group and 4 in
control group• Anders 1998 (76 eyes): 3 subretinal haemorrhage in radiation
group, 3 in control group• Kobayashi 2000 (101 eyes): 2 people in radiation group
complained of "transient conjunctival injection that resolved
within 2 weeks"• Marcus 2001 (83 eyes): 1 case of retinal detachment and 1 case
of vitreous haemorrhage in the radiation group• RAD 1999 (205 eyes): 4 deaths unrelated to radiation treatment,
3 in radiation group, 1 in control group
We judged this to be low-certainty evidence. We downgraded one
level for risk of bias (eight out of the nine studies were high
risk of bias in one or more domain) and downgraded one level
for imprecision (the individual studies were small with imprecise
estimates).
1.7 Number of anti-VEGF injections
This outcome was introduced in the current update and is only
relevant to the next comparison where anti-VEGF was combined
with radiotherapy.
2. Radiotherapy combined with anti-VEGF versus anti-VEGF
alone for neovascular AMD 
Four studies considered this comparison: two studies were of
external beam radiotherapy (INTREPID 2013; Osmanovic 2017)
and two studies of epimacular brachytherapy (CABERNET 2013;
MERLOT 2016). INTREPID 2013 used IRay Radiotherapy System
(Oraya Therapeutics, Newark, CA) to deliver ionising radiation
targeted at the neovascular lesions. Two of the studies were three-
arm studies with two intervention groups of 24 Gy and 16 Gy
(INTREPID 2013; Osmanovic 2017). For the purposes of the analysis,
we combined the intervention groups using the RevMan calculator.
The other studies used 24 Gy dose. Three studies used ranibizumab
(0.5 mg, PRN) in radiation and control groups; Osmanovic 2017
used either ranibizumab or bevacizumab. INTREPID 2013 and
Osmanovic 2017 were sham-controlled.
2.1 Loss of 3 or more lines of best-corrected visual acuity
People receiving radiotherapy combined with anti-VEGF are
probably more likely to lose 3 or more lines of BCVA over 12 months
compared with people having anti-VEGF alone (RR 2.11, 95% CI 1.40
to 3.17; eyes = 1050; studies = 3; I2 = 0%) (Analysis 2.1). Two of
these studies were of epimacular brachytherapy (CABERNET 2013;
MERLOT 2016) and these had a higher risk (RR 2.36 95% CI  1.49
to 3.74) than the one study of stereotactic radiotherapy (INTREPID
2013) (RR 1.24, 95% CI  0.50 to  3.11) although the formal  test for
subgroup diEerences was not statistically significant (P = 0.22). We
judged this moderate-certainty evidence, downgrading for risk of
bias (two of the studies were at risk of performance and detection
bias).
Two studies  reported data at 24 months (820  eyes) (CABERNET
2013; MERLOT 2016). There was an increased risk of loss of 3
or more lines in people treated with radiotherapy plus anti-VEGF
compared with people treated with anti-VEGF alone (RR 2.39, 1.68
to 3.39) (Analysis 2.2).
2.2 Change in best-corrected visual acuity
Four studies reported this outcome at 12 months. Three of the
studies reported logMAR letters. We converted this to logMAR
score by multiplying the mean and standard deviation by 0.02 and
changing the direction of the mean value by multiplying by -1 (as a
larger logMAR score represents poorer vision). For two studies that
had three arms we combined the 16 Gy and 24 Gy groups using the
RevMan calculator. For Osmanovic 2017 standard deviations were
not reported. We attempted to estimate the standard deviation
using information in the paper (P values) but this produced values
that appeared too small and gave this small study much too much
weight in the analysis (of the order of 25%). We decided to impute
the standard deviation by using values from the other included
studies. The included studies ranged from standard deviations of
approximately 0.2 to 0.3 so we chose a standard deviation of 0.25.
There was considerable heterogeneity (Analysis 2.4). Results
ranged from a small mean diEerence of -0.03 logMAR in favour of
radiotherapy combined with anti-VEGF (INTREPID 2013; Osmanovic
2017) to a mean diEerence of 0.13 logMAR (CABERNET 2013) and
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0.08 logMAR (MERLOT 2016) in favour of anti-VEGF alone. With an
I2 of 82% we took the decision not to pool these data. Subgroup
analysis suggested a diEerent eEect in studies of external beam
radiotherapy (MD -0.03 logMAR, 95% CI -0.09 to 0.03; participants =
252; studies = 2; I2 = 0%) and studies of epimacular brachytherapy
(MD 0.10 logMAR, 95% CI 0.05 to 0.15; participants = 820; studies =
2; I2 = 50%, test for interaction P = 0.0007).
We judged this to be low-certainty evidence, downgrading for risk
of bias (three of the four studies were high risk of bias in one or more
domains) and inconsistency.
Two studies  reported data at 24 months (819  eyes) (CABERNET
2013; MERLOT 2016). The mean diEerence in change visual acuity
in the radiotherapy with anti-VEGF group was 0.17 logMAR (worse)
(CI 0.11 to 0.23) compared with anti-VEGF alone (Analysis 2.2). Both
studies were of epimacular brachytherapy.
2.3 Contrast sensitivity
None of the included studies reported this outcome.
2.4 New vessel growth
There were inconsistent results on size of the CNV at 12 months with
one study finding increased lesion size with radiotherapy group
whereas the other two studies found small diEerences (one in
favour of radiotherapy, one not). One study did not report results
disaggregated by treatment group. We judged this to be very low-
certainty evidence, downgrading one level for risk of bias (two of
the studies were at risk of performance and detection bias), one
level for imprecision (two of the individual studies estimates were
imprecise) and one level for inconsistency (there was no consistent
pattern to the individual study results).
Size of CNV at 12 months (continuous)
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Radiation therapy with anti-VEGF Anti-VEGF aloneStudy
Mean SD n Mean SD n
Mean difference (95% CI) Comments
CABER-
NET
2013
1.9 2.7 245 -3.0 7.2 124 4.90 (3.59 to 6.21) Change in mean total lesion size in
mm2 at 24 months
INTRE-
PID
2013
0.75 0.32 59 0.79 0.27 46 -0.04 (-0.15 to 0.07) CNV area mm2
MER-
LOT
2016
1.2 8.3 219 0.4 7.6 110 0.80 (-1.00 to 2.60) Change in total lesion size mm2
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SD: Standard deviation
Osmanovic 2017 noted that the lesion area measured on FA
decreased from 1.61 (SD 1.10) mm2 at baseline to 0.73 (SD 0.85)
mm2 at one year for the overall study population. No diEerences
were noted between the two intervention groups (16 and 24 Gy)
and the sham irradiation group (data not reported for groups
individually).
2.5 Quality of life
None of the included studies reported this outcome.
2.6 Adverse e/ects
In CABERNET 2013 the radiotherapy and anti-VEGF treatment group
had a higher proportion of ocular adverse events (54%) compared
to the anti-VEGF alone (18%). The majority of these adverse events
were cataract. Overall 5% of the treatment group had radiation
device-related adverse events (17 cases); 10 of these cases were
radiation retinopathy.
INTREPID 2013 reported that adverse eEects were similar across
study arms and none were attributed to radiation.
In MERLOT 2016 the radiotherapy plus anti-VEGF group (n
= 244) there were four cases of reduced visual acuity, one
vitreous haemorrhage, three retinal haemorrhage, three retinal
detachment, one vision blurred, one endophthalmitis, one vitreous
floaters, two postoperative uveitis. In the anti-VEGF alone group (n
= 119) there was one case of reduced visual acuity and one case of
retinal haemorrhage.
Osmanovic 2017 reported no radiation associated adverse eEects
and no vascular adverse events. Four out of 13 phakic eyes had
cataract progression (one from the control and three from the
radiation group).
2.7 Number of anti-VEGF injections
This outcome was introduced in the current update and is
only relevant to the four studies  that combined anti-VEGF with
radiotherapy (CABERNET 2013; INTREPID 2013; MERLOT 2016;
Osmanovic 2017).
There were some diEerences in average number of injections given
between the four studies. In three of the four studies, the anti-VEGF
alone group on average received more injections.
 
  Radiotherapy with anti-VEGF Anti-VEGF alone
Study Number of
loading injec-
tions planned
Total mean number of injections (SD) Number of
loading injec-
tions planned
Total mean number of injec-
tions (SD)
CABER-
NET 2013
2 (baseline,
month 1)
12 months: (3.7)
24 months: (h6.2)
3 (baseline,
month 1,
month 2)
12 months: (6.2)
24 months: (10.4)
INTREPID
2013
1 (baseline) 12 months:
16-Gy: 2.64 (2.46) (median, 2; range, 0 to 10)
24-Gy: 2.43 (2.40) (median, 2; range, 0 to 10)
1 (baseline) 12 months:
3.74 (2.57) (median, 3.5; range, 0
to 10)
MERLOT
2016
0* 4.8 (3.2)
4.5 (3.8)
0* 4.1 (2.4)
4.2 (2.7)
Osman-
ovic 2017
3 16-Gy: 3.52 (range 4 to 8)
24-Gy: 3.83 (range 3 to 5)
3 6.13 (range 3 to 8)
 
SD: Standard deviation
*Quote: "Inclusion criteria included completion of a loading phase
of 3 anti-VEGF induction injections, followed by ongoing monthly
PRN therapy, with a minimum of 4 ranibizumab treatments in the
previous 12 months or 2 ranibizumab treatments in the previous 6
months."
D I S C U S S I O N
Summary of main results
We included 18 studies (n = 2430 people, 2432 eyes) of radiation
therapy with dosages ranging from 7.5 to 24 Gy.These studies
mainly took place in Europe and North America but two studies
were from Japan and one multicentre study included sites in
South America. Three of these studies investigated brachytherapy
(plaque and epimacular), the rest were studies of external beam
radiotherapy including one trial of stereotactic radiotherapy.
Four studies compared radiotherapy combined with anti-vascular
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endothelial growth factor (anti-VEGF) with anti-VEGF alone. Eleven
of the studies gave no radiotherapy treatment to the control group;
five studies used sham irradiation; and one study used very low-
dose irradiation (1 Gy) and one study used a mixture of sham
irradiation and no treatment. FiJeen studies were judged to be at
high risk of bias in one or more domains.
For the comparison radiotherapy versus no radiotherapy, our
results suggest little or no diEerence in loss of 3 lines of vision at
12 months (low-certainty evidence). We observed a small benefit
in average visual acuity at 12 months for radiotherapy; there
was some evidence of possible publication bias (low-certainty
evidence). Low-certainty evidence suggested a small benefit in
average contrast sensitivity at 12 months but the eEect was small
and we judged the certainty of the evidence to be low. Growth
of new vessels (largely change in CNV size) was variably reported
and It was not possible to produce a summary estimate of this
outcome. The studies were small with imprecise estimates and
there was no consistent pattern to the study results (very low-
certainty evidence). Quality of life was only reported in one study of
199 people; there was no clear diEerences between treatment and
control groups (low-certainty evidence). Six out of 14 studies did
not report on adverse eEects. Seven studies reported on radiation
retinopathy or neuropathy or both. Five of these studies reported
no radiation-associated adverse eEects. One study of 88 eyes
reported one case of possible radiation retinopathy. One study
of 74 eyes graded retinal abnormalities in some detail and found
that 72% of participants who had radiation, compared with 71%
of participants in the control group, had retinal abnormalities
resembling radiation retinopathy or choroidopathy. Four studies
reported cataract surgery or progression: events were generally
low and no consistent evidence of any increased occurrence in
the radiation group. One study noted transient disturbance of the
precorneal tear film but no evidence from the other two studies that
reported dry eye of any increased risk with radiation therapy. None
of the participants received anti-VEGF injections.
When radiotherapy was combined with anti-VEGF and compared
to anti-VEGF alone, people receiving radiotherapy plus anti-VEGF
were had worse visual outcomes which was probably largely
attributable to the epimacular brachytherapy technique which
involves pars plana vitrectomy. Anti-VEGF regimens with fewer
injections may be associated with less visual gain (Kim 2016,
Li 2020) and this may be another explanation for worse visual
outcomes in the radiotherapy group in unmasked studies. None of
the included studies reported contrast sensitivity or quality of life.
Growth of new vessels (largely change in CNV size) was variably
reported in three studies (803 eyes); It was not possible to produce
a summary estimate. There was no consistent pattern to the
study results (very low-certainty evidence). For adverse outcomes,
variable results were reported in the 4 studies. In 3 studies reports
of adverse events were low and no radiation-associated adverse
events reported. In one study the radiotherapy and anti-VEGF
treatment group had a higher proportion of ocular adverse events
(54%) compared to the anti-VEGF alone (18%). The majority of
these adverse events were cataract. Overall 5% of the treatment
group had radiation device-related adverse events (17 cases); 10 of
these cases were radiation retinopathy.
There is one large ongoing study (STAR (NCT02243878))
involving over 400 participants in 10 UK centres. Stereotactic
radiotherapy combined with ranibizumab is being compared to
sham radiotherapy plus ranibizumab alone with estimated study
completion in 2024.
Overall completeness and applicability of evidence
Although there are 18  trials published, the overall completeness
of the evidence is less than might be expected from the number
of trials. This is because of the diEerent dosages used, diEerent
outcome measures and diEerent follow-up times reported. Most
studies included in this review took place before the use of anti-
VEGF became widespread, and before the development of modern
radiotherapy techniques, such as stereotactic radiotherapy. We
observed worse visual outcomes with epimacular brachytherapy,
and there is an increased risk of  adverse events with that
technique. The role of modern radiotherapy, in combination with
anti-VEGF, is currently uncertain. It may oEer the potential to reduce
the need for anti-VEGF retreatment, and there are ongoing studies
addressing this question.
Quality of the evidence
The evidence was largely judged to be of low-certainty, depending
on the outcome. We downgraded for risk of bias because of
limitations in the studies, particularly in regard to selection,
performance and detection bias. We also downgraded for
imprecision because the confidence intervals included no eEect or
clinically unimportant diEerences. We could assess publication bias
for only one outcome - change in visual acuity at 12 months - and
this showed an asymmetric plot indicative of publication bias.
The applicability of this evidence is also limited by diEerences in
inclusion criteria and study design among studies. For example,  in
CABERNET 2013, an unmasked study, patients received a loading
phase  of three injections in the anti-VEGF-alone arm and two
injections in the combined radiotherapy arm. The lack of masking
may have led to a further tendency to prescribe fewer injections in
the combination arm, which may have led to less visual gain. Lack
of masking may have influenced the attitude towards prescription
of anti-VEGF injections also in Osmanovic 2017. Another limitation
is in the inclusion of patients with newly diagnosed versus chronic
active CNV, such as in Osmanovic 2017 and INTREPID 2013. Finally,
the mean number of injections was small in some studies. This
caused skewed estimates, with mean values being similar to their
standard deviations.
Potential biases in the review process
There have been many changes to both AMD treatment and
Cochrane methods since the protocol for this review was first
published in 2002. As such, many of the decisions have been made
post-hoc. In the case of Cochrane methods, the introduction of
new methods is unlikely to have introduced bias, indeed, it is likely
to have improved the overall robustness of the review. When it
comes to incorporating new evidence, the key decision was how
to incorporate trials where radiotherapy was combined with anti-
VEGF. Given that the baseline risk for many outcomes included
in this review is so diEerent with anti-VEGF, and given the overall
context in which the studies took place, we took the decision
to add in a separate comparison to this review. An alternative
approach may have been to consider these as a subgroup. However,
given that the eEects were so diEerent, and that we included an
additional outcome of number of injections, we felt that it was
clearer to consider these as a separate comparison. We feel that
either approach would have produced similar results. Similarly,
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we had discussion about the heterogeneity in radiotherapy
interventions in the more recent studies. We considered external
beam radiotherapy and epimacular brachytherapy as subgroups;
as the results were quite diEerent we have presented the results of
this subgroup analysis in the abstract.
Agreements and disagreements with other studies or
reviews
Other reviews, in general, acknowledge the disappointing results
with external beam radiotherapy and focus on the potential role
of more targeted radiotherapy techniques - either stereotactic and
brachytherapy (plaque or epimacular) - in combination with anti-
VEGF therapy (Englander 2013; Kishan 2013; Mendez 2013; Silva
2011). These other reviews are narrative, rather than systematic,
and discuss a broader section of the literature, including non-
randomised studies.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The results of this review are uncertain regarding the use of
radiotherapy in people with neovascular AMD; the majority of the
studies took place before the use of anti-VEGF became widespread
and before the development of modern radiotherapy techniques
such as stereotactic radiotherapy. Visual outcomes with epimacular
brachytherapy are likely to be worse and there is an increased
risk of   adverse events with that technique.  The role of modern
radiotherapy, in combination with anti-VEGF, is currently uncertain;
ongoing studies are assessing its role in reducing the need for anti-
VEGF retreatment.
Implications for research
Given the results of this review, further research on radiotherapy
for neovascular AMD may not be justified until current ongoing
studies, in particular the STAR trial, have reported. Future trials
should have a suEicient sample size to detect moderate eEects and
should report data on visual acuity outcomes so as to enable their
inclusion in systematic overviews. Consistent reporting of data on
factors such as lesion size and composition would also facilitate
synthesis. Adequate masking of the treatment groups should be
considered a priority. Current ongoing studies are addressing the
issue as to whether radiotherapy combined with anti-VEGF may
reduce the need to anti-VEGF retreatment.
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Study characteristics
Methods Parallel group RCT
One eye per person, unclear how selected
Participants Country: Japan
Number of participants (eyes) enrolled: NR
Number of participants (eyes) excluded after randomisation: NR
Number of participants (eyes) ana lysed at 12 months: 69 (69)
Average age: 72 years (range NR)
Sex: 30% women
Inclusion criteria:
• At least 60 years of age• Worsening of symptoms or clinical features within 12 months• A best corrected visual acuity is 20/200 or more• CNV with AMD was assessed by FA or IA• A maximum CNV size was one optic-disk diameter• CNV located at the fovea or the edge of CNV within 200 micro meters from the fovea• Signature on the Informed Consent Form with ability to fully understand the informed consent7
Exclusion criteria:
• Under 60 years of age• Difficult to asses the size of CNV• Cataract with less-visible fundus• History of diabetes• History of hypertension• Optic neuropathy
Interventions Intervention: (n=38)
• External beam radiation therapy (10 fractions of 2Gy)• Duration: NR
Comparator: (n=31)
• Observation
Outcomes Primary: NR
Secondary: NR
Reported:
• Visual acuity (logMAR)• Size of CNV (by FA or IA).
Follow-up: 12 months
Notes Date conducted: NR
Sources of funding: NR
AMDLRTSG 2003 
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Declaration of interest: NR
Trial id: NR
Information from translation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Judgement comment: not reported
Allocation concealment
(selection bias)
Unclear risk Judgement comment: not reported
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
High risk Judgement comment: masking was not mentioned in the report. We judged
that participants and personnel were probably not masked which may have af-
fected  the visual acuity outcome.
Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Low risk Judgement comment: masking was not mentioned in the report. We judged
that participants and personnel were probably not masked but felt that lack of
masking was unlikely to lead to performance bias for this outcome. 
 
Blinding of outcome as-
sessment (detection bias)
Visual acuity
High risk Judgement comment: masking was not mentioned in the report. It is possible
that an individual’s performance on the visual acuity test could be influenced
by their perceptions as to which treatment they received.
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
High risk Judgement comment: masking was not mentioned in the report.
Incomplete outcome data
(attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (re-
porting bias)
High risk Study was planned as 2-year study enrolling 100 participants but only 69 par-
ticipants reported after one year.
AMDLRTSG 2003  (Continued)
 
 
Study characteristics
Methods Parallel group RCT
One eye per person
Multicentre study: 10 sites
Participants Country: US
Number of participants (eyes) randomised: 88 (88)
Number of participants (eyes) excluded after randomisation: NR
AMDRT 2004 
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Number of participants (eyes) ana lysed at 12 months: 62 (62)
Average age: 77 years (63 to 92)
Sex: 58% women
Inclusion criteria:
• Age 50 or older• New or recurrent CNV secondary to AMD• Occult CNV or minimally classic or predominately classic subfoveal CNV• CNV not amenable to laser treatment or participant refuses• <50% fibrosis• No ocular histoplasmosis• No ocular conditions precluding good photography• No other ocular condition likely to affect visual acuity in 2 years• Myopia <=8 diopters• Acuity >= 20/320
Exclusion criteria:
• Diabetes• Prior ocular/periocular radiation• CNV secondary to non-AMD causes• Prior or current chemotherapy• History of macula affecting drugs
Interventions Intervention: (n=41)
• External beam radiation therapy (5 fractions of 4 Gy)
Comparator: (n=47)
• Observation (n=25)• Sham radiotherapy (n=22)
Outcomes Primary:
• Loss of 3 or more lines of visual acuity• 5 to 8 working days
Secondary:
• Lesion size graded on fluorescein angiography.• Side effects.
Follow-up: 12 months
Notes Full trial name: Age-related macular degeneration radiotherapy trial (AMDRT).
Date conducted: January 2000 to December 2001
Sources of funding: Supported by grant R21 EY12341 from the National Eye Institute, National Institutes
of Health, Department of Health and Human Services and institutional funds from each of the partici-
pating centres.
Declaration of interest: NR
Trial id: NR
Planned sample size 100 participants; stopped early because of a low rate of recruitment.
AMDRT 2004  (Continued)
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote "Randomised treatment assignment schedules, stratified by lesion type
(new or recurrent) and status of blood (<50% or >=50% of the lesion) were gen-
erated for each clinical site" Page 819, methods, enrolment and randomisation
procedures, 2nd paragraph.
Judgement comment: not clear how the allocation schedule was generated.
Allocation concealment
(selection bias)
Low risk Quote “After required examinations and photography were completed, an eli-
gibility checklist was faxed to the Coordinating Center. The enrolling ophthal-
mologist and clinic coordinator verbally confirmed eligibility of the patient by
telephone with a Coordinating Center staE member. For centres performing
sham radiotherapy, sealed, black-lined security envelopes containing a ran-
domized assignment were provided to the ophthalmology clinical staE. At en-
rollment, the clinic co-ordinator confirmed with the Co-ordinating center the
assignment of the patient to the next sequentially numbered envelope for the
appropriate strata. The sealed envelope was sent to the Radiation Oncology
Department and opened by the radiation oncologist and radiation physicist
immediately before treatment. For centers not performing sham radiothera-
py, the coordinator called the Co-ordinating center to obtain the treatment as-
signment" Page 819, methods, enrolment and randomisation procedures, 1st
and 2nd paragraphs.
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
High risk Quote: “At the outset, each center had the option to choose sham radiothera-
py or observation only as the control treatment for active radiotherapy. Three
centers chose sham radiotherapy.” Page 819, methods, 1st paragraph.
Judgement comment: participants and personnel were not masked in 7 out of
10  centres (25/47 participants) which may have affected the visual acuity out-
come.
 
Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Low risk Quote: “At the outset, each center had the option to choose sham radiothera-
py or observation only as the control treatment for active radiotherapy. Three
centers chose sham radiotherapy.” Page 819, methods, 1st paragraph.
 
Judgement comment: participants and personnel were not masked in 7 out of
10  centres  (25/47 participants) . We  felt that lack of masking was unlikely to
lead to performance bias for this outcome. 
Blinding of outcome as-
sessment (detection bias)
Visual acuity
High risk Quote: “At the outset, each center had the option to choose sham radiothera-
py or observation only as the control treatment for active radiotherapy. Three
centers chose sham radiotherapy.” Page 819, methods, 1st paragraph. “Dur-
ing follow-up, examiners were masked to the patient’s treatment assignment”
Page 820, 1st paragraph.
Judgement comment: it was obvious which group received radiotherapy. Only
3 out of 10 centres chose to perform sham radiotherapy. Only some of the con-
trol group (22/47) received sham radiotherapy. Visual acuity assessment was
masked to treatment group, however, it is possible that an individual’s perfor-
mance on the visual acuity test could be influenced by their perceptions as to
which treatment they received.
Blinding of outcome as-
sessment (detection bias)
Low risk Quote: “Certified photographers performed all fundus photography and flu-
orescein angiography following SST protocols. Initial visit photography was
AMDRT 2004  (Continued)
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Lesion size on fluorescein
angiography
required within 42 days of enrollment. Expert readers at the FPRC, masked to
treatment assignment, reviewed all baseline photographs and angiograms for
eligibility.” Page 820, photography and fluorescein angiography, 1st and 2nd
paragraphs.
Although the report does not explicitly state that photograph graders were
masked to treatment assignment when considering follow-up photographs
and angiograms it is highly likely that they were and it is unlikely that a partici-
pant’s knowledge of treatment group would influence the appearance of pho-
tographs or fluorescein angiograms.
Incomplete outcome data
(attrition bias)
All outcomes
High risk 31/41 (76%) in treatment group seen at 12 months; 31/47 (66%) of the control
group seen at 12 months. 12 randomised participants were subsequently con-
sidered ineligible; all these participants included in the analysis. 5 participants
did not get the treatment they were assigned but were analysed in the original
group to which they were assigned.  
Quote: “Among all missed visits, the most common reason for not complet-
ing the visit was patient refusal; other reasons were illness and transportation
problems”
The follow-up in the control group was rather low which is why this is marked
“no”.
Selective reporting (re-
porting bias)
Unclear risk No access to study protocol or trial registry entry.
AMDRT 2004  (Continued)
 
 
Study characteristics
Methods Parallel group RCT
Unclear whether one or both eyes enrolled
Participants Country: Germany
Number of participants (eyes) randomised: 76 (?)
Number of participants (eyes) excluded after randomisation:NR
Number of participants (eyes) analysed: 76 (6 months) and 37 (12 months)
Average age: 77 years (range NR)
Sex: 67% women
Inclusion criteria:
• fluorescein angiography detectable classic subfoveal choroidal neovascular membranes;• no foveal bleeding• history of severe visual impairment does not exceed 6 months• visual acuity is not better than 0.5 and no worse than 0.05• age over 50 years• no previous laser photocoagulation of macular• no previous irradiation of the region• no other eye diseases that could deteriorate the visual acuity• opportunity to participate in further follow-up up to 5 years
Anders 1998 
Radiotherapy for neovascular age-related macular degeneration (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
36
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Exclusion criteria: NR
Interventions Intervention: (n=39)
• External beam radiation therapy (6 fractions of 2Gy)• Duration: 8 days
Comparator: (n=37)
• Observation
Outcomes Primary: NR
Secondary: NR
Reported:
• Near visual acuity• Distance visual acuity• Metamorphopsia by Amslernetz• Complications including subretinal haemorrhage and lens opacity
Follow-up: 3, 6 and 12 months
Notes Date conducted:NR
Sources of funding: NR
Declaration of interest: NR
Trial id: NR
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Judgement comment: not reported.
Allocation concealment
(selection bias)
Unclear risk Judgement comment: not reported.
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
High risk Judgement comment: masking was not mentioned in the report. We judged
that participants and personnel were probably not masked which may have af-
fected visual acuity outcome.
Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Low risk Judgement comment: masking was not mentioned in the report. We judged
that participants and personnel were probably not masked but felt that lack of
masking was unlikely to lead to performance bias for this outcome. 
Blinding of outcome as-
sessment (detection bias)
Visual acuity
High risk Not reported and groups different
Blinding of outcome as-
sessment (detection bias)
High risk Not reported and groups different
Anders 1998  (Continued)
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Lesion size on fluorescein
angiography
Incomplete outcome data
(attrition bias)
All outcomes
High risk 19/39 (49%) radiation group and 18/37 (49%) control group seen at 12 months.
No information as to the reason for loss to follow-up given.
Selective reporting (re-
porting bias)
Unclear risk No access to study protocol or trial registry entry.
Anders 1998  (Continued)
 
 
Study characteristics
Methods Parallel group RCT
One eye per person, unclear how eye was selected - described as "affected eye"
Participants Country: The Netherlands
Number of participants (eyes) randomised: 74 (74)
Number of participants (eyes) excluded after randomisation: 3 (3)
Number of participants (eyes) analysed: 68 (68) (at 3 months) 63 (63) (at 12 months)
Average age: 75 years (range NR)
Sex: 56% women.
Inclusion criteria:
• Recent drop in central vision (within 2 months)• Best-corrected Snellen visual acuity >0.1• Angiographically proven classic, occult or mixed type subfoveal CNV• Clinical signs of ARM, e.g., drusen or pigment epithelial changes• Age > 55 years• Informed consent• No previous laser photocoagulation in the macular area• No radiation treatment for ear, nose, throat or brain disease• No diabetes mellitus
Exclusion criteria: NR
Interventions Intervention: (n=36)*
• External beam radiation therapy (4 fractions of 6Gy)• Duration: 3 weeks
Comparator: (n=32)*
• Observation
*Number randomised not reported. This is the number in each group at 3 months.
Outcomes Primary: NR but sample size calculation based on loss of 1 or more lines of Snellen acuity ending up
with visual acuity <0.1.
Secondary: NR
Bergink 1998 
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Reported:
• Visual acuity (loss of 3 or more lines and loss of 6 or more lines)• Size of the CNV
Follow-up: 3, 6 and 12 months
Notes Date conducted: NR
Sources of funding:NR
Declaration of interest: NR
Trial id: NR
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "...patients were assigned randomly to either radiation treatment or
observation." Page 322
Judgement comment: not clear how the allocation schedule was generated. 
Allocation concealment
(selection bias)
Unclear risk Judgement comment: not reported.
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
High risk Quote: "The patients in the control group did not receive a sham radiation
treatment" Page 322.
Judgement comment:  participants and personnel were not masked which
may have affected the visual acuity outcome.
Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Low risk Quote: "The patients in the control group did not receive a sham radiation
treatment" Page 322.
 Judgement comment: participants and personnel were not masked but we
felt that lack of masking was unlikely to lead to performance bias for this out-
come. 
Blinding of outcome as-
sessment (detection bias)
Visual acuity
High risk Quote: "The patients in the control group did not receive a sham radiation
treatment" Page 322.
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
Low risk Quote: "The readers were blinded for treatment status." Page 322
Incomplete outcome data
(attrition bias)
All outcomes
High risk Quote "Initially, 74 patients were included in the study. Of these, one died and
two stopped before the first control, one because of fear of malignancies due
to the treatment. In addition, one was excluded because of previously unnot-
ed diabetes mellitus and two patients showed insufficient evidence for CNV on
the angiogram later on. As a result, 68 patients, 36 in the treatment group and
32 in the observation group completed at least 3 months/ follow-up. Twelve
months follow-up was obtained in 63 patients." Page 322.
No information on the numbers originally randomised to treatment and con-
trol.
Bergink 1998  (Continued)
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Selective reporting (re-
porting bias)
High risk Outcome on which sample size was based not reported
Bergink 1998  (Continued)
 
 
Study characteristics
Methods Parallel group RCT
One eye included in study; if both eyes were eligible, then the eye with the worse VA was treated.
Participants Country: US, Europe, Israel, South America
Number of participants (eyes) randomised: 494 (494)
Number of participants (eyes) excluded after randomisation: 0
Number of participants (eyes) analysed: 457 (457)
Average age: 77 years (range 50 to 96)
Sex: 68% women
Inclusion criteria:
• age 50 or older• predominantly classic, minimally classic, or occult with no classic lesions, as determined by the Inves-
tigator, secondary to AMD, with a total lesion size (including blood, scarring, and neovascularization)
of < 12 total disc areas (21.24 mm2), and a GLD ≤5.4 mm• primary (newly diagnosed and untreated) or recurrent lesions (previously diagnosed and regressed
but currently presenting with a new, active component)• ETDRS best corrected visual acuity of 69 to 24 letters (20/40 to 20/320 Snellen Equivalent) in the study
eye• if both eyes eligible, one with worse acuity selected; if only one eye eligible, vision in the non-study
eye was 20/400 or better• subretinal haemorrhage (if any) not more than 50% of total lesion size, and not involving the subfoveal
space• minimally classic and occult with no classic lesions must have evidence of presumed recent disease
progression defined as:(i) The presence of subretinal haemorrhage and/or fluid and/or lipid or (ii) loss
of one or more lines of vision (ETDRS or equivalent) during previous six months or FA documented
lesion growth by ≥ 10% during past 6 months• women post-menopausal #1 year or surgically sterilized or negative serum pregnancy test required
within 14 days prior to randomisation
Exclusion criteria:
In the study eye:
• prior or concurrent treatment for neovascular AMD or glaucoma• prior or concomitant disease• CNV lesion contained more than 25% scarring and/or atrophy• inadequate pupillary dilation or significant media opacities• vitreous haemorrhage• history of rhegmatogenous retinal detachment or macular hole• any intraocular surgery of the study eye within 12 weeks prior to the screening visit, with the exception
of cataract surgery
CABERNET 2013 
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• Other systemic conditions/treatments and/or any other condition preventing from completing the
study (details in online appendices to published paper)
Interventions Intervention: (n=331)
• Epimacular brachytherapy (standardised point dose of 24Gy)• 2 intravitreal injections of 0.5mg ranibizumab, one at the end of surgery and one 30 days later
Comparator: (n=163)
• Ranibizumab (0.5mg) 3 injections, over 3 months followed by quarterly injections
Epimacular brachytherapy was delivered by an intraocular strontium 90/yttrium 90 (Sr90/Y90) applica-
tor device designed to deliver local, targeted radiation to the neovascular tissue associated with wet
AMD.
Participants were followed up monthly and received an additional injection if one or more of the re-
treatment criteria were met. Retreatment was mandated if any of the following applied: loss of 10 let-
ters of VA, verified by repeat testing within 7 days; 50-µm increase in OCT central retinal thickness; new
subretinal haemorrhage;or new neovascularization visible using FA.
Outcomes Primary (at 24 months)
• Proportion of participants losing fewer than 15 ETDRS letters of BCVA from baseline• Proportion of participants gaining 15 ETDRS letters or more of BCVA
Secondary (at 24 months)
• Mean change in BCVA• Mean change in FA lesion size• Mean change in OCT central foveal thickness• Mean number of ranibizumab retreatments
Follow-up:12 and 24 months
Notes Full study name: CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy (CABERNET)
Date conducted: June 2007 to September 2009
Sources of funding: Study was sponsored by the manufacturer of the device - NeoVista
Declaration of interest: “The sponsor (NeoVista, Inc) participated in the design, conduct, data collection,
data management, data analysis, interpretation of the data, preparation, review, and approval of the
manuscript”
Trial registration ID number: NCT00454389
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Randomization was stratified by study center, type of lesion (predom-
inantly classic, minimally classic, or occult), and baseline VA (53 letters or 53
letters) using a 2:1 randomization scheme in favor of EMBT" Page 319
 
Judgement comment: unclear how the schedule was generated.
Allocation concealment
(selection bias)
Unclear risk Judgement comment: not reported
CABERNET 2013  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
High risk Quote: "Because this study involved a surgical intervention and sham surgery
with a nonradioactive probe was not believed to be ethically appropriate,
masking to study treatment was not possible for the treating surgeon and the
patient; however, the VA examiner and the reading centers that reviewed all
optical coherence tomography (OCT) and FA images were masked." Page 319
Judgement comment: participants and personnel were not masked which
may have affected the visual acuity outcome. 
Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Unclear risk Quote: "Because this study involved a surgical intervention and sham surgery
with a nonradioactive probe was not believed to be ethically appropriate,
masking to study treatment was not possible for the treating surgeon and the
patient; however, the VA examiner and the reading centers that reviewed all
optical coherence tomography (OCT) and FA images were masked." Page 319
Judgement comment: participants and personnel were not masked. We felt
that it was unclear what effect this would have on lesion progression.  
Blinding of outcome as-
sessment (detection bias)
Visual acuity
High risk Quote: "Because this study involved a surgical intervention and sham surgery
with a nonradioactive probe was not believed to be ethically appropriate,
masking to study treatment was not possible for the treating surgeon and the
patient; however, the VA examiner and the reading centers that reviewed all
optical coherence tomography (OCT) and FA images were masked." Page 319
Although visual acuity assessment was masked to treatment group, physi-
cians and participants were not. It is possible that an individual’s performance
on the visual acuity test could be influenced by their perceptions as to which
treatment they received.
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
Low risk Quote: "Because this study involved a surgical intervention and sham surgery
with a nonradioactive probe was not believed to be ethically appropriate,
masking to study treatment was not possible for the treating surgeon and the
patient; however, the VA examiner and the reading centers that reviewed all
optical coherence tomography (OCT) and FA images were masked." Page 319
Incomplete outcome data
(attrition bias)
All outcomes
Low risk 302/331 (91%) in the intervention arm were analysed and 155/163 (95%) of
comparator arm.
Selective reporting (re-
porting bias)
High risk Outcomes pre-specified at 12 months (on trials registry entry) but reported at
24 months.
CABERNET 2013  (Continued)
 
 
Study characteristics
Methods Parallel group RCT
One eye per person. "In patients with bilateral disease, all had marked disparity in visual acuity between
the two eyes. The eye with better vision, having worse than 20/40 best-corrected visual acuity, was en-
tered in the trial, except for five patients in whom the treated eye was worse than 20/40 and the fellow eye
had better acuity."
Participants Country: USA.
Number of participants (eyes) randomised: 27 (27)
Number of participants (eyes) excluded after randomisation: NR
Char 1999 
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Number of participants (eyes) analysed: 27 (27)
Average age: 76 years (range 64 to 89)
Sex: 52% women
Inclusion criteria:
• Subfoveal CNV secondary to AMD with visual acuity less than 20/40.
Exclusion criteria: NR
Interventions Intervention: (n=14)
• External beam radiation therapy (1 fraction of 7.5 Gy)
Comparator: (n=13)
• Observation
Outcomes Primary: NR
Secondary: NR
Reported:
• Visual acuity (ETDRS chart)• Changes in subretinal neovascular area and membrane edge
Follow-up: Every 3 months, average follow-up 17 months (range 0 to 32 months)
Notes Date conducted: NR
Sources of funding: "This study was supported in part by a grant from That Man May See, San Francisco,
California, an unrestricted grant from Research to Prevent Blindness Inc, New York, New York, and an un-
restricted grant from the Tumori Foundation, San Francisco, California."
Declaration of interest: NR
Trial id: NR
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients were randomly assigned to either no treatment or to treat-
ment with...." Page 575, methods.
Judgement comment: unclear how the allocation sequence was generated. 
Allocation concealment
(selection bias)
Unclear risk Judgement comment: not reported.
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
High risk Quote: "... visual acuity examination with refraction by a trained ophthalmic
technician, who was masked to the patients' status in the trial" Page 575,
methods.
Judgement comment: participants and personnel were not masked which
may have affected the visual acuity outcome.
Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Low risk Quote: "Initial and serial fluorescein angiograms were read in a masked man-
ner by two observers...." Page 575, methods.
Char 1999  (Continued)
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Judgement comment: participants and personnel were not masked.  We felt
that lack of masking was unlikely to lead to performance bias for this out-
come. 
Blinding of outcome as-
sessment (detection bias)
Visual acuity
High risk Quote: "... visual acuity examination with refraction by a trained ophthalmic
technician, who was masked to the patients' status in the trial" Page 575,
methods.
Judgement comment: However, patients were not masked which may influ-
ence visual acuity assessment.
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
Low risk Quote: "Initial and serial fluorescein angiograms were read in a masked man-
ner by two observers...." Page 575, methods.
Judgement comment: Lack of masking of participants is unlikely to influence
this outcome.
Incomplete outcome data
(attrition bias)
All outcomes
High risk Judgement comment: 27 participants were entered in the trial with a mean
follow-up of 15 months (range of 7 to 32 months). In the radiation group mean
follow-up was 17 months. In the group assigned to observation the mean fol-
low-up was 16 months. In the methods it states that participants "were fol-
lowed on a 3-month basis" however it was not clear from the report why differ-
ent participants had different lengths of follow-up.
Selective reporting (re-
porting bias)
Unclear risk Judgement comment: no access to study protocol or trial registry entry.
Char 1999  (Continued)
 
 
Study characteristics
Methods Parallel group RCT
Probably one eye per person as refer to "affected eye", unclear how selected
Participants Country: USA.
Number of participants (eyes) randomised: 37 (?37)
Number of participants (eyes) excluded after randomisation: 7 (?7)
Number of participants (eyes) analysed: 24 (?24) (at 12 months) 13 (?13) (at 24 months)
Average age: 71 years (median) (range NR)
Sex: 38% women.
Inclusion criteria:
• subfoveal CNV due to age-related macular degeneration• subjective visual acuity impairment of affected eye of less than 6 months’ duration• best-corrected visual acuity of the affected eye of 20/40 and 20/400
Exclusion criteria:
• inability to maintain steady fixation with either eye• preexisting microangiopathy, including diabetic retinopathy• media opacity sufficient to preclude examination and follow-up• inability to give informed consent• inability to comply with follow-up regimen
Ciulla 2002 
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Interventions Intervention: (n=30*)
• External beam radiation therapy (2 fractions of 8 Gy)• Duration: 2 days
Comparator: (n=10*)
• Sham External beam radiation therapy (not described
*37 participants recruited but "No data were recovered from seven subjects owing to four baseline
discrepancies, one oD-protocol treatment due to equipment failure, and two discontinuations before the
first treatment". NR which groups these 7 lost to follow-up belonged to.
Outcomes Primary: NR
Secondary: NR
Reported (but data available only for visual acuity):
• Visual acuity (logMAR, ETDRS chart)• CNV size and leakage• Subretinal haemorrhage
Follow-up: 3, 6, 12, 18 and 24 months
Notes Date conducted: June 1998 to January 2000
Sources of funding: "Supported by the Indiana Lions Club, by an unrestricted grant from Research to Pre-
vent Blindness, Inc, New York, New York, and by an Intercampus Research Grant from Research and Uni-
versity Graduate School, Indiana University and the Pearl Vision Foundation. Doctor Ciulla is a recipient of
a Career Development Award from Research to Prevent Blindness, Inc."
Conflict of interest: NR
Trial id: NR
Other information: "Recruitment was halted at 37 subjects for ethical reasons regarding randomization
to sham treatment when Food and Drug Administration approval of Visudyne (Novartis Ophthalmics, Du-
luth, Georgia, USA) was anticipated."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Judgement comment: not reported.
Allocation concealment
(selection bias)
Unclear risk Judgement comment: not reported.
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
Low risk Quote: "A randomized, sham-controlled clinical trial"  Description of study in
title, abstract and methods page 905.
 Quote "Masked assessment of angiography and analysis of visual acuity be-
tween groups were performed" Page 905.
Judgement comment: although this statement is not very clear as to whether
the measurement of visual acuity was masked as the control group had sham
irradiation we have assumed that measurement of visual acuity was masked.
Ciulla 2002  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Low risk Quote: "Masked assessment of angiography and analysis of visual acuity be-
tween groups were performed" Page 905.
Judgement comment: although this statement is not very clear as to whether
the measurement of visual acuity was masked as the control group had sham
irradiation we have assumed that as the trial was sham-controlled participants
and personnel were masked. 
Blinding of outcome as-
sessment (detection bias)
Visual acuity
Low risk Quote: "Masked assessment of angiography and analysis of visual acuity be-
tween groups were performed" Page 905.
Judgement comment: although this statement is not very clear as to whether
the measurement of visual acuity was masked as the control group had sham
irradiation we have assumed that measurement of visual acuity was masked.
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
Low risk Quote: "Masked assessment of angiography and analysis of visual acuity be-
tween groups were performed" Page 905.
Judgement comment: although this statement is not very clear as to whether
the measurement of visual acuity was masked as the control group had sham
irradiation we have assumed that measurement of visual acuity was masked.
Incomplete outcome data
(attrition bias)
All outcomes
High risk Quote: "Of the 37 subjects enrolled in this investigation [...] no data were re-
covered from seven subjects owing to four baseline discrepancies, one oE-pro-
tocol treatment due to equipment failure, and two discontinuations before the
first treatment." Page 906.
Judgement comment: no information was given as to which treatment group
these exclusions belonged to and only data for 30 participants analysed. At 12
months, 16/20 and 7/10 participants in treatment and control group respec-
tively seen (page 906, table 1). No reason was given for this loss to follow-up.
Selective reporting (re-
porting bias)
Unclear risk Judgement comment: no access to study protocol or trial registry entry.
Ciulla 2002  (Continued)
 
 
Study characteristics
Methods Parallel group RCT
One eye per person, unclear how eye selected
Participants Country: Germany.
Number of participants (eyes) randomised: 45 (45)
Number of participants (eyes) excluded after randomisation: NR
Number of participants (eyes) analysed: 42(42)
Average age: 74 years (range 45 to 92)
Sex: 57% women.
Inclusion criteria:
• Age 45+ years• Classic/occult subfoveal CNV• Informed consent
Eter 2002 
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• No prior radiation treatment to head• No vascular eye disease• Neovascularisation as a results of AMD alone• No prior treatment of AMD.
Exclusion criteria: NR
Interventions Intervention: (n=27)*
• Exernal beam radiation therapy (10 fractions of 2 Gy)• Duration: "3 times a week" so assume duration is approximately 3 weeks
Comparator: (n=15)*
• Observation
* This is the number followed up. Original allocation not reported; 3 participants lost to follow-up.
Outcomes Primary: NR
Secondary: NR
Reported:
• Visual acuity (logMAR)• Membrane size
Follow-up: 6 months
Notes Date conducted: NR
Sources of funding: NR
Declaration of interest: NR
Trial id: NR
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Forty-five eyes of 45 patients [...] were assigned randomly in a ratio of
2:1 to either radiation treatment or observation." Page 14
Judgement comment: authors did not describe how the allocation sequence
was generated. 
Allocation concealment
(selection bias)
Unclear risk Judgement comment: not reported.
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
High risk Judgement comment: masking was not mentioned in the report. We judged
that participants and personnel were probably not masked which may have af-
fected the visual acuity outcome.
Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Low risk Judgement comment: the control group was observation only so we have as-
sumed that participants and personnel were not masked. We felt that lack of
masking was unlikely to lead to performance bias for this outcome. 
Eter 2002  (Continued)
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Blinding of outcome as-
sessment (detection bias)
Visual acuity
High risk Judgement comment: as control group was observation only we have as-
sumed visual acuity assessment not masked.
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
Low risk Judgement comment: control group was observation only we have assumed
participants and personnel were not masked. We  felt that lack of masking was
unlikely to lead to performance bias for this outcome. 
Incomplete outcome data
(attrition bias)
All outcomes
High risk Quote: "Although 45 patients were randomized to either treatment or fol-
low-up, 27 patients in the radiation group and 15 patients in the control group
could be enrolled in the study. Three patients were lost to follow-up because
motivation for further examinations was low and because they needed to be
accompanied by relatives due to their age and visual acuity." Page 14.
Judgement comment:  no information was given as to which group the exclud-
ed participants belonged. No information was given as to numbers examined
at six month follow-up.
Selective reporting (re-
porting bias)
Unclear risk Judgement comment: no access to study protocol or trial registry entry.
Eter 2002  (Continued)
 
 
Study characteristics
Methods Parallel group RCT
One eye per person, unclear how selected
Participants Country: Europe, multi-centre
Number of participants (eyes) randomised: 230 (230)
Number of participants (eyes) excluded after randomisation: 0
Number of participants (eyes) analysed: 230 (230)
Average age: 74 years (range NR)
Sex: 69% women
Inclusion criteria:
• Neovascular age-related macular degeneration (AMD) diagnosed within the previous 3 years, have
received at least three injections with Lucentis® (ranibizumab) or Avastin® (bevacizumab) within the
previous year, and have the need for treatment with anti‒vascular endothelial growth factor (VEGF)
therapy due to increased fluid or persistent cysts on optical coherence tomography (OCT), or leakage
on fluorescein angiography (FA).• Total lesion size of <12 disc areas and a CNV lesion with the greatest linear dimension of <6 mm, but
not greater than 3 mm from the centre of the fovea to the furthest point on the lesion perimeter.• Distance from the cent er of the fovea to the nearest edge of the optic disc should be not less than
3 mm.• At least 50 years of age• Women must be post-menopausal for ≥1 year or surgically sterilized, or a pregnancy screen must be
performed prior to the study and a reliable form of contraception approved by the investigator must
be maintained during the study• Best corrected visual acuity of 75 to 25 letters in the study eye and at least 20 letters in the fellow eye.
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Exclusion criteria:
• CNV due to causes other than AMD, including ocular histoplasmosis syndrome, angioid streaks, mul-
tifocal choroiditis, choroidal rupture, or pathologic myopia (spherical equivalent ≥ ‒8 diopters)• Axial length of <20 mm or >26 mm• Previously diagnosed with diabetes mellitus and/or a haemoglobin A1c (HbA1c) value of >6.5%, and
with retinal findings consistent with diabetic retinopathy• Prior or concurrent therapies for AMD, including submacular surgery, subfoveal thermal laser pho-
tocoagulation (with or without photographic evidence), transpupillary thermotherapy (TTT), ocular
photodynamic therapy, radiation therapy to the head or neck in the study eye.• Previous posterior vitrectomy, or any surgery in the study eye within 6 months or YAG (yttrium-alu-
minum-garnet) capsulotomy within 3 months prior to the screening visit.• Intravitreal device in the study eye.• Concomitant disease in the study eye including uveitis, acute ocular or periocular infection, retinal
vasculopathies (including retinal vein occlusions, etc.) or intraocular pressure ≥30 mmHg uncontrol-
lable with medications.• History of rhegmatogenous retina detachment, optic neuritis, or intraocular tumours in the study eye.• Inadequate pupillary dilation or significant media opacities in the study eye, including cataract, which
may interfere with visual acuity or the evaluation of the posterior segment.• Likely to need cataract surgery during the 2-year study period
Interventions Intervention 1: (n=75)
• External beam (stereotactic) radiation therapy (1 fraction of 16Gy)• Ranibizumab (0.5mg) day 0 and as needed (pro re nata, PRN)
Intervention 1: (n=75)
• External beam (stereotactic) radiation therapy (1 fraction of 24 Gy)• Ranibizumab (0.5mg) day 0 and PRN
Comparator: (n=80)
• Sham radiation• Ranibizumab (0.5mg) day 0 and PRN
External beam radiation therapy was delivered by the IRay Radiotherapy System (Oraya Therapeutics,
Newark, CA)).
"To be eligible for additional ranibizumab injections, participants had to meet 1 or more of the follow-
ing retreatment criteria: a 100-m increase in central subfield thickness from the lowest previous OCT
measurement, new or increased macular hemorrhage documented by fundus photographs, or a 5-let-
ter or more decrease in BCVA since the last visit or the baseline BCVA, with disease activity, for example,
persistent or increased fluid on OCT or leakage on FA."
Outcomes Primary outcome:
• Number of PRN ranibizumab injections administered over 52 weeks.
Secondary were:
• Mean change in best-corrected visual acuity (BCVA) based• Loss of fewer than 15 letters,• Gain of 15 letters or more• Gain of 0 letters or more,• Time from mandatory ranibizumab injection at day 0 to the first PRN ranibizumab injection• Change in total lesion size on fluorescein angiography, and change in CNV lesion size on FA. S• Adverse events (AEs) and serious AEs (SAEs).
INTREPID 2013  (Continued)
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Follow-up: Every 4 weeks to 52 weeks
Notes Full study name: IRay in Conjunction with Anti-VEGF Treatment for Patients with Wet AMD (INTREPID)
Date conducted: December 2009 to April 2013
Sources of funding: Oraya Therapeutics
Declaration of interest: Quote “Oraya Therapeutics participated in the design of the study, conducting
the study, data collection, data management, data analysis, and review of the manuscript.” All authors
report support from Oraya therapeutics
Trial id: NCT01016873
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "A dynamic randomization algorithm was used to balance for the fol-
lowing: whether the patient exhibited a dry macula at any time after previ-
ous anti-VEGF therapy, whether the diagnosis of wet AMD was fewer than 6
months, or 6 months or more before study entry, and whether the baseline
(day 0) visual acuity score was 54 letters or fewer, or 55 letters or more." Page
1894
Quote: “A stochastic minimization algorithm,25 using a minimization probabil-
ity parameter of 0.80, was used for dynamic randomization. The balance used
for the minimization algorithm changed 3 times in the study, but the final in-
tended ratio at the end of enrolment achieved the intended 2:1:2:1 distribu-
tion.“ Page 1894
Allocation concealment
(selection bias)
Low risk Quote: "Treatment assignment and dose were acquired through a secure,
password-protected website." Page 1894
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
Low risk Quote: "All patients and study personnel, including personnel from the spon-
sor, were masked to active or sham treatments." Page 1894
Quote “The operator of the SRT device was not masked to whether the partic-
ipant was receiving the 16-Gy or 24-Gy dose because the treatment times dif-
fered. However, all study personnel, including the operator, were masked to
whether active or sham treatment was delivered for the chosen dose.“ Page
1895
Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Low risk Quote: "All patients and study personnel, including personnel from the spon-
sor, were masked to active or sham treatments." Page 1894
Quote: “The operator of the SRT device was not masked to whether the partic-
ipant was receiving the 16-Gy or 24-Gy dose because the treatment times dif-
fered. However, all study personnel, including the operator, were masked to
whether active or sham treatment was delivered for the chosen dose.“ Page
1895
Blinding of outcome as-
sessment (detection bias)
Visual acuity
Low risk Quote: "All patients and study personnel, including personnel from the spon-
sor, were masked to active or sham treatments." Page 1894
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
Low risk Quote: "All patients and study personnel, including personnel from the spon-
sor, were masked to active or sham treatments." Page 1894
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Incomplete outcome data
(attrition bias)
All outcomes
Low risk Judgement comment: similar numbers followed up to one year: 16Gy 74/75 24
Gy 72/75 and sham 79/80.
Selective reporting (re-
porting bias)
Low risk Judgement comment: outcomes on trial register same as in published report
INTREPID 2013  (Continued)
 
 
Study characteristics
Methods Parallel group RCT
One eye per person for most participants, 2 participants had 2 eyes enrolled
Participants Country: Finland.
Number of participants (eyes) randomised: 86 (88)
Number of participants (eyes) excluded after randomisation: 0
Number of participants (eyes) analysed: 82 (84) (at 12 months) 76 (78) at 3 years
Average age: 76 years .
Sex: 60% women
Inclusion criteria:
• Recent angiographically proven exudative AMD with subfoveal CNV• Best-corrected visual acuity (VA) of 20/200 or better• Size of the lesion had to be no larger than 6 disc areas and not exceed the boundaries of the active
area of the plaque to be used• At least ambulatory vision had to be present in the other eye
Exclusion criteria:
• Age 55 years or younger• Uncontrolled or advanced glaucoma, diabetes, cataract precluding angiography, or• estimation that surgery would be required within 3 years
Interventions Intervention: (n=43, 43 eyes)
• Episceral brachytherapy (Sr90 plaques*)
Comparator: (n=43, 45 eyes)
• Observation
*"Two different plaque types were used. Plaque I had a diameter of 8 mm and delivered a dose of 15 Gy
at a depth of 1.75 mm in 54 minutes. With plaque II, the corresponding values were 4 mm, 12.6 Gy, and 11
minutes"
Outcomes Primary:
• Visual acuity (ETDRS)
Secondary:
• Contrast sensitivity
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• Changes in the macula
Follow-up: 6, 12, 24 and 36 months
Notes Date conducted: 1996 to 2000
Sources of funding: Eye Foundation, Helsinki, Finland, and Friends of the Blind (De Blindas Vänner—
Sokeain Ystävät ry), Helsinki, Finland.
Declaration of interest: Reported "none".
Trial id: NR
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Judgement comment: not reported.
Allocation concealment
(selection bias)
Unclear risk Quote: "Treatment allocation was performed by envelope randomization with-
in CNV categories, as described below." Page 568.
Judgement comment: not really enough information to judge whether this
was done properly.
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
High risk Quote: "Visual acuity was measured [...] by an examiner masked against the
treatment given to the patient." Page 569
Judgement comment: participants were probably not masked which may have
affected the visual acuity outcome.
Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Low risk Quote: "The angiograms were evaluated in a masked manner...." Page 569.
 
Judgement comment: participants were unmasked but performance bias un-
likely to affect the lesion size
Blinding of outcome as-
sessment (detection bias)
Visual acuity
High risk Quote: "Visual acuity was measured [...] by an examiner masked against the
treatment given to the patient." Page 569
Judgement comment: participants were not masked which may have affected
measurement of visual acuity.
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
Low risk Quote: "The angiograms were evaluated in a masked manner...." Page 569
Incomplete outcome data
(attrition bias)
All outcomes
Unclear risk Judgement comment: 43/43 participants in radiotherapy group seen at 12
months however it was also reported that two participants had died in the in-
terim. 39/43 participants in the control group (91%) seen at 12 months. Flow
chart was confusing because at 6 months it was reported that four participants
refused and at 12 months it was reported one participant refused. However
same numbers 39/43 seen at both time points. Page 569, figure 1.
Selective reporting (re-
porting bias)
Unclear risk Judgement comment: no access to study protocol or trial registry entry.
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Study characteristics
Methods Parallel group RCT
Unclear how many eyes
Participants Country: UK
Number of participants (eyes) randomised: 58 (?)
Number of participants (eyes) excluded after randomisation: NR
Number of participants (eyes) analysed: unclear
Average age: 76 years (range 56 to 86)
Sex: 61% women (but reported for intervention arm only)
Inclusion criteria:
• Aged 50+ with subfoveal CNV (classic) and evidence of AMD e.g. drusen• Visual acuity > 6/60
Exclusion criteria:
• Diabetes• Severe hypertension• Retinal vascular disease• Myopia
Interventions Intervention: (n=38)
• External beam radiation therapy (4 fractions of 4.5 Gy)• Duration: NR
Comparator: (n=20)
• Observation.
Outcomes Primary: NR
Secondary: NR
Reported:
• Visual acuity (ETDRS)• Contrast sensitivity and angiography mentioned but not reported
Follow-up: 3, 6 and 12 months
Notes Date conducted: NR
Sources of funding: NR
Declaration of interest: NR
Trial id: NR
Risk of bias
Bias Authors' judgement Support for judgement
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Random sequence genera-
tion (selection bias)
Unclear risk Quote:"Patients [...] were randomised to between treatment and control".
Page 7
Judgement comment: authors did not describe how the allocation schedule
was generated. 
Allocation concealment
(selection bias)
Unclear risk Judgement comment: not reported.
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
High risk Judgement comment: masking was not mentioned in the report. We judged
that participants and personnel were probably not masked which may have af-
fected the visual acuity outcome.
Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Low risk Judgement comment: participants were unmasked but performance bias un-
likely to affect the lesion size.
Blinding of outcome as-
sessment (detection bias)
Visual acuity
High risk Judgement comment: no masking was reported and there was no sham inter-
vention in the control group.
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
High risk Judgement comment: no masking was reported and there was no sham inter-
vention in the control group.
Incomplete outcome data
(attrition bias)
All outcomes
High risk Judgement comment: initial allocation was 38 participants in the treatment
arm and 20 for the control arm. 27 participants in treatment arm versus 20 in
control arm reported at 12 months. No information on people not seen.
Selective reporting (re-
porting bias)
Unclear risk Judgement comment: no access to study protocol or trial registry entry.
Kacperek 2001  (Continued)
 
 
Study characteristics
Methods Parallel group RCT
One eye per person, chosen by participant and clinician
Participants Country: Japan
Number of participants (eyes) randomised: 101 (101)
Number of participants (eyes) excluded after randomisation: NR
Number of participants (eyes) analysed: 85 (85) at all time points to 24 months
Average age: 72 years (range 60 to 89)
Sex: 64% women
Inclusion criteria:
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• Unsuitable for laser photocoagulation under the Macular Photocoagulation Study criteria, (2) newly
formed or exacerbated choroidal neovascular membranes (e.g., within 3 months)• Visual acuity of 0.5 (25/50) or worse• Age of 60 years of more
Exclusion criteria:
• Pre-existing ocular disease (i.e., glaucoma, severe myopia, chronic inflammatory disease, or neoplas-
tic disorders)• Systemic disorders (diabetes, uncontrolled hypertension) or a known life-threatening disease.
Interventions Intervention: (n=51)
• External beam radiation therapy (10 fractions of 2 Gy)• Duration: 14 days
Comparator: (n=50)
• Observation
Outcomes Primary: NR
Secondary: NR
Reported:
• Visual acuity (ETDRS)• Area of CNV (FFA)• Safety
Follow-up: 2 weeks, 1, 3, 6, 9, 12, 18 and 24 months
Notes Date conducted: NR
Sources of funding: Hyogo Prefecture and Hyogo Medical Society, Hyogo, Japan.
Declaration of interest: NR
Trial id: NR
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "One eye of each of the 101 patients was prospectively randomized to
receive radiotherapy or no treatment." and "Within 24 hours after enrollment,
the patients were randomized by means of computer-generated numbers;
patients assigned 0 received low-dose radiotherapy and those assigned 1 re-
ceived no treatment." Page 618
Allocation concealment
(selection bias)
Low risk Quote: "The treating physician (HK) was unaware of the patients' randomiza-
tion state". Page 618
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
High risk Judgement comment: masking of participants was not mentioned in the re-
port. We judged that participants were probably not masked which may have
affected the visual acuity outcome.
Blinding of participants
and personnel (perfor-
mance bias)
Low risk Judgement comment: masking of participants was not mentioned in the re-
port. We judged that participants were probably not masked but performance
bias unlikely to affect the lesion size.
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Lesion size on fluorescein
angiography
Blinding of outcome as-
sessment (detection bias)
Visual acuity
High risk Quote: "Assessment of outcomes, including visual acuity, angiographic in-
terpretation, and assessment of complications and adverse events, was per-
formed in a masked fashion." Page 618
Judgement comment: participants were not masked which may have affected
measurement of visual acuity.
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
Low risk Quote: "Assessment of outcomes, including visual acuity, angiographic in-
terpretation, and assessment of complications and adverse events, was per-
formed in a masked fashion." Page 618
Incomplete outcome data
(attrition bias)
All outcomes
Unclear risk Quote: "The overall complete follow-up rate was 84.1% (85/101) (Table 1 and
Figure 1). there was no significant difference between the two groups; the
complete follow-up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment
group and control group, respectively. Six treated patients and 10 untreated
patients were not evaluated, because five patients died with intercurrent dis-
ease, six patients were to ill or frail to attend, and it was not possible to contact
five patients. Page 619, results.
Judgement comment: although follow-up was over 80% there were some dif-
ferences between the intervention and comparator group. 
Selective reporting (re-
porting bias)
Unclear risk Judgement comment: no access to study protocol or trial registry entry.
Kobayashi 2000  (Continued)
 
 
Study characteristics
Methods Parallel group RCT
One eye per person, unclear how eye selected
Participants Country: USA.
Number of participants (eyes) randomised: 83 (83)
Number of participants (eyes) excluded after randomisation: NR
Number of participants (eyes) analysed: 70 (70) (at 12 months)
Average age: 76 years (range NR)
Sex: 61% women
Inclusion criteria:
Active subfoveal CNV secondary AMD
Older than 48 years of age
Visual acuity > 20/400
Clinical and angiographic evidence of a choroidal neovascular membrane
Exclusion criteria:
Previous laser treatment
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Choroidal neovascularisation due to other causes
Retinal vascular diseases e.g. diabetes; previous ocular, orbital or periorbital radiation; likely candi-
dates for chemotherapeutic agents
Interventions Intervention: (n=41)
• External beam radiation therapy (7 fractions of 2 Gy)• Duration: 7 working days
Comparator: (n=42)
• Sham treatment (1 session)• Duration: 1 day
Outcomes Primary:
• Distance visual acuity (logMAR, ETDRS)
Secondary:
• Contrast sensitivity (Pelli-Robson chart)• Appearance of fundus
Follow-up: specified as 3, 6, 12, 24 weeks, and every 6 months to 4 years but only data up to 12 months
reported.
Notes Date conducted: February 1995 to September 1998
Sources of funding: Grant from Research to Prevent Blindness, New York and grants from the Knights
Templar Educational Foundation of Georgia.
Declaration of interest: NR
Trial id: NR
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The randomization incorporated blocking, which is recommended any
time patient recruitment extends for a long period of time. Blocks of size 2 or 4
were assigned randomly, and a separate random permutation was used to as-
sign the 2 treatments to the blocks." Page 172
Allocation concealment
(selection bias)
High risk Quote "A randomization schedule was printed and sent to the radiology team,
who then sequentially allocated the patients to the sham or actual radiation
treatments". Page 172
Judgement comment: allocation schedule was clearly not concealed. 
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
Low risk Quote: "The patient, examining ophthalmologist, and ophthalmic techni-
cian were unaware of the assignment to observation or radiation treatment
groups." Page 172
Judgement comment: study was sham-controlled. 
Blinding of participants
and personnel (perfor-
mance bias)
Low risk Quote: "The patient, examining ophthalmologist, and ophthalmic techni-
cian were unaware of the assignment to observation or radiation treatment
groups." Page 172
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Lesion size on fluorescein
angiography
Blinding of outcome as-
sessment (detection bias)
Visual acuity
Low risk Quote: "The patient, examining ophthalmologist, and ophthalmic techni-
cian were unaware of the assignment to observation or radiation treatment
groups." Page 172
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
Low risk Quote: "The patient, examining ophthalmologist, and ophthalmic techni-
cian were unaware of the assignment to observation or radiation treatment
groups." Page 172
Incomplete outcome data
(attrition bias)
All outcomes
High risk Judgement comment: differences in follow-up between groups and follow-up
less than 80% in the control group. Radiation group n=41. 37 (90%) seen at one
year, 4 with missing data. Control n=42. 33 (79%) seen at one year, 6 with miss-
ing data, 3 withdrawn. Page 175, table 2.
Selective reporting (re-
porting bias)
High risk Judgement comment: follow-up to 4 years but only data up to 12 months re-
ported.
Marcus 2001  (Continued)
 
 
Study characteristics
Methods Parallel group RCT
One eye per person, if both eyes eligible participant chose which eye would be treated
Participants Country: UK (24 hospitals)
Number of participants (eyes) enrolled: 363 (363)
Number of participants (eyes) excluded after randomisation: 
Age: 77 years (range 56 to 96)
Sex:  60% women 
Inclusion criteria:
• Subfoveal choroidal neovascularisation associated with wet age-related macular degeneration.• Retinal Angiomatous Proliferation (RAP) lesions not directly involving the fovea must be associated
with contiguous foveal leakage demonstrated on fundus examination, OCT, or fluorescein angiogra-
phy• Received anti-VEGF induction treatment, defined as the first three months of anti-VEGF therapy. Fol-
lowing this induction period, participants must have received at least 4 additional injections of Lu-
centis® in no more than 12 months preceding enrolment, or 2 additional injections of Lucentis® in no
more than 6 months preceding enrolment, given on an as needed basis• Aged 50 years or older and met the NICE treatment criteria for Lucentis® therapy, i.e. all of the follow-
ing circumstances must apply in the eye to be treated: the best-corrected visual acuity is between
6/12 and 6/96 (24 to 69 ETDRS letters) there is no permanent structural damage to the central fovea
the lesion size is less than or equal to 12 disc areas in greatest linear dimension there is evidence of
recent presumed disease progression (blood vessel growth, as indicated by fluorescein angiography,
or recent visual acuity changes)
Exclusion criteria:
• Has not been treated in accordance with NICE guidance• Visual acuity worse than 6/96 at the time of study enrolment
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• Prior or concurrent subfoveal CNV therapy with agents, surgery or devices (other than Macugen®,
Avastin®, or Lucentis®) including thermal laser photocoagulation (with or without photographic evi-
dence), photodynamic therapy, intravitreal or subretinal steroids, and transpupillary thermotherapy
(TTT)• Subfoveal scarring• Active concomitant disease in the study eye, including uveitis, presence of pigment epithelial tears or
rips, acute ocular or periocular infection;• Previously diagnosed with Type 1 or Type 2 Diabetes Mellitus or retinal findings consistent with Type
1 or Type 2 Diabetes Mellitus;• Advanced glaucoma (greater than 0.8 cup:disk) or intraocular pressure ≥ 30 mmHg in the study eye• Previous glaucoma filtering surgery in the study eye• Inadequate pupillary dilation or significant media opacities in the study eye, including cataract, which
may interfere with visual acuity or the evaluation of the posterior segment;• Current vitreous haemorrhage in the study eye• History of rhegmatogenous retinal detachment or macular hole in the study eye;• CNV due to causes other than AMD, including known or suspected idiopathic polypoidal choroidal vas-
culopathy (IPCV), ocular histoplasmosis syndrome, angioid streaks, multifocal choroiditis, choroidal
rupture, or pathologic myopia (spherical equivalent ≥ 8 Dioptre or axial length ≥ 25mm);• Any intraocular surgery in the study eye within 12 weeks prior to the screening visit, with the exception
of cataract surgery• Previous cataract surgery within 2 months prior to enrolment into the study;• Known serious allergies to fluorescein dye used in angiography;• Known sensitivity or allergy to Lucentis®;• Previous radiation therapy to the eye, head or neck;• An intravitreal device or drug in the study eye;• Any other condition, which in the judgment of the investigator would prevent completing the study
(e.g. documented diagnosis of dementia or serious mental illness);• Current participation in another drug or device clinical trial, or participation in such a clinical trial
within the last year;• History of use of drugs with known retinal toxicity, including: chloroquine (Aralen - an anti-malari-
al drug), hydroxychloroquine (Plaquenil), phenothiazines, chlorpromazine (Thorazine), thioridazine
(Mellaril), fluphenazine (Prolixin), perphenazine (Trilafon), and trifluoperazine (Stelazine)• Unwilling or unable to return for scheduled treatment and follow-up examinations for three years• Women must be post-menopausal more than 1 year unless surgically sterilised
Interventions Intervention: (n=244)
• Epimacular brachytherapy, Strontium-90 (24 Gy)• Ranibizumab (0.5mg) monthly as required
Comparator: (n=119)
• Ranibizumab (0.5mg) monthly as required
Outcomes Primary: 
• Mean change in ETDRS best-corrected visual acuity at 24 months• Number of re-treatment injections of Lucentis® per participant, per year
Secondary:  
• Percentage losing < 15 ETDRS letters• Percentage gaining ≥ 0 ETDRS letters• Percentage gaining ≥ 15 ETDRS letters• Change in total lesion size by fluorescein angiography• Change in total CNV size by fluorescein angiography• Foveal thickness measured using OCT.
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Follow-up: 24 months
Information from clinicaltrials.gov
Notes Date conducted: November 2009 to January 2012 
Sources of funding:  Quote "NeoVista (Fremont, CA) provided unrestricted research funding but had no
role in data collection, analysis, or in the preparation or review of this manuscript"
Declaration of interest:  Authors reported financial support from NeoVista
Trial id: NCT01006538 
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Online electronic randomization was  undertaken immediately af-
ter eligibility was confirmed by recruiting sites using a commercial system
(MedSciNet, Stockholm, Sweden)." 
Allocation concealment
(selection bias)
Low risk Quote: "Online electronic randomization was undertaken immediately af-
ter eligibility was confirmed by recruiting sites using a commercial system
(MedSciNet, Stockholm, Sweden)." 
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
High risk Judgement comment: participants and personnel were not masked which
may have affected the visual acuity outcome.
Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Unclear risk Judgement comment: participants and personnel were not masked and it is
unclear whether this would have affected lesion size (for example, by differen-
tial treatment with anti-VEGF). 
Blinding of outcome as-
sessment (detection bias)
Visual acuity
Low risk Quote: "VA testing and macular imaging (which were the most commonly used
criteria to necessitate ranibizumab retreatment) were undertaken by masked
assessors."
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
Low risk Quote: "VA testing and macular imaging (which were the most commonly used
criteria to necessitate ranibizumab retreatment) were undertaken by masked
assessors."
Incomplete outcome data
(attrition bias)
All outcomes
Low risk Judgement comment: at 12 months, 13/363 (3.3%) participants were missing
visual acuity measurements. These were imputed using multiple imputation.
The ranibizumab retreatment injection analysis also included all participants
but no correction was made for participants who withdrew early. Fluorescein
angiography and OCT data were not available for 26 (7.2%) and 19 (5.2%) of
eyes respectively.   
Selective reporting (re-
porting bias)
Low risk Judgement comment: outcomes on trials registry entry were reported
MERLOT 2016  (Continued)
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Study characteristics
Methods Parallel group RCT
One eye included in study; if both eyes were eligible, then the eye with the worse VA was treated.
Participants Country:  USA
Number of participants (eyes) randomised:  30 (30)
Number of participants (eyes) excluded after randomisation: 8 (8)
Number of participants (eyes) analysed:  22 (22)
Average age:  77 years (range not reported)
Sex:  59% women
 
Inclusion criteria:
• newly diagnosed neovascular AMD or evidence of recurrent active neovascular AMD.• subfoveal or juxtafoveal choroidal neovascularization identified by fundus fluorescein angiography• best-corrected visual acuity of 6/12 to 6/120 (20/40 to 20/400)
Exclusion criteria:
 
• additional macular or optic nerve comorbidities,• history of diabetes mellitus• history of prior head and neck radiation• intravitreal anti-VEGF treatment in the study eye within the 6 weeks before enrolment
Eyes with newly diagnosed neovascular AMD were recruited preferentially, but eyes with less than
three prior intravitreal anti-VEGF therapies and with recurrent active neovascular AMD were considered
for study enrolment.
Interventions Intervention 1: (n=7)
 
• External beam radiation therapy (2 fractions of 12 Gy)
Intervention 2: (n=7)
• External beam radiation therapy (2 fractions of 8 Gy)
Comparator: (n=8)
• Sham radiation therapy (2 sessions)
Duration: 24 hours apart. 
Radiation was administered 2 weeks to 6 weeks after enrolment and administration of the first study
intravitreal anti-VEGF therapy. All participants received anti-VEGF therapy (either ranibizumab 0.5mg
or bevacizumab 1.25mg in 0.05mL). 
Quote "For sham radiation, a thermoplastic head mask was used to immobilize the head and eyelid re-
tractors were used to remove the eyelids from the sham radiation field. Eye fixation was monitored and
maintained for the sham radiation. The sham treatment was identical to the actual proton beam treat-
ment except no treatment planning was performed and no radiation was administered."
Outcomes Outcomes specified on clinical trials registry
Osmanovic 2017 
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Primary outcome: 
• Incidence of severe vision loss from radiation retinopathy or other causes defined as number of eyes
with 3 or more lines of vision loss from baseline at 12 and 24 months
Secondary (12 and 24 months):
 
• number of anti-VEGF therapy [ Time Frame: Month 12 and 24 ]• number of eyes with 3 or more lines of visual acuity gain from baseline• number of eyes with radiation retinopathy or papillopathy
Outcomes reported in the publication (12 months) 
• Mean best-corrected visual acuity• Cataract progression• Lesion area of CNV membrane• Resolution of leakage on FA• OCT measurements, mean CRT• Size of PED• Number of intravitreal anti-VEGF treatments• Radiation retinopathy or papillopathy• Severe vision loss (loss of BCVA of 3 or more Snellen lines)• Adverse arteriothromboembolic events
Notes Full study name: ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative
Age-related Macular Degeneration (AMD) (PBAMD2)
 
Date conducted: September 2010 to January 2015
 
Sources of funding:  Quote: "Supported in part by a Strategic CTSI grant from UCSF (K.M.) and Research
to Prevent Blindness Unrestricted Grant."
 
Declaration of interest: Quote: "The authors made the following disclosures: L.M.: Contracted research-
 Genentech, Allergan, Roche/Novartis. A.M.: Contracted research Genentech, Allergan, Roche/Novartis;
Honoraria Genentech. S.S.P.: Contracted research e Genentech, Allergan, Roche/Novartis; Honoraria
Genentech."
 
Trial id: NCT01213082
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The randomization was conducted by the unmasked study coordina-
tor using a sequential coin toss, first to determine sham versus PBT, then 1 of 2
doses of PBT if subject was randomized to PBT." 
Allocation concealment
(selection bias)
High risk Quote: "The randomization was conducted by the unmasked study coordina-
tor using a sequential coin toss, first to determine sham versus PBT, then 1 of
2 doses of PBT if subject was randomized to PBT. Because this is a small study,
the total enrollment of each study group was roughly equal throughout the
study with variations in enrollment number limited to within 2 subjects rela-
tive to the other study groups during the study after accounting for any sub-
jects who
were excluded from the study after study enrollment."
Osmanovic 2017  (Continued)
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Judgement comment: Allocation was unmasked. 
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
Low risk Quote: "Both the examining study ophthalmologist and study subject were
masked to study group randomization until study completion. The radiation
oncologist and the randomizing study coordinator were unmasked to study
randomization and did not participate in follow-up study examination and an-
ti-VEGF retreatment decision
making. For the interim 1-year data analysis, 1 investigator (E.M.) not involved
in follow-up study eye examination and anti-VEGF retreatment decision mak-
ing was unmasked."
Judgement comment: sham radiation in the control group. 
Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Low risk Quote:  "Both the examining study ophthalmologist and study subject were
masked to study group randomization until study completion. The radiation
oncologist and the randomizing study coordinator were unmasked to study
randomization and did not participate in follow-up study examination and an-
ti-VEGF retreatment decision making. For the interim 1-year data analysis, 1
investigator (E.M.) not involved in follow-up study eye examination and an-
ti-VEGF retreatment decision making was unmasked."
Judgement comment: sham radiation in the control group. 
Blinding of outcome as-
sessment (detection bias)
Visual acuity
Low risk Quote:  "Both the examining study ophthalmologist and study subject were
masked to study group randomization until study completion. The radiation
oncologist and the randomizing study coordinator were unmasked to study
randomization and did not participate in follow-up study examination and an-
ti-VEGF retreatment decision making. For the interim 1-year data analysis, 1
investigator (E.M.) not involved in follow-up study eye examination and an-
ti-VEGF retreatment decision making was unmasked."
Judgement comment: sham radiation in the control group. 
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
Low risk Quote: "Both the examining study ophthalmologist and study subject were
masked to study group randomization until study completion. The radiation
oncologist and the randomizing study coordinator were unmasked to study
randomization and did not participate in follow-up study examination and an-
ti-VEGF retreatment decision making. For the interim 1-year data analysis, 1
investigator (E.M.) not involved in follow-up study eye examination and an-
ti-VEGF retreatment decision making was unmasked."
Judgement comment: sham radiation in the control group. 
Incomplete outcome data
(attrition bias)
All outcomes
High risk Judgement comment:  22/30 participants followed up to one year (73%) and
not clear follow-up by group in published study report. On clinical trials reg-
istry follow-up was  lower in the control group: at 24 months 6/12 (50%) in
24Gy group, 7/11 (64%) and 4/11 (in sham irradiation group (36%). Reason for
loss to follow-up given on trials registry was "lost to follow-up". 
Selective reporting (re-
porting bias)
High risk Judgement comment: differences between outcomes pre-specified on the
clinical trials registry and outcomes reported in the paper. 
Osmanovic 2017  (Continued)
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One eye per person, unclear how selected
Participants Country: Germany
Number of participants (eyes) randomised: 205 (205)
Number of participants (eyes) excluded after randomisation: 11 (11) (participant DNA)
Number of participants (eyes) analysed: 183 (183) at 12 months
Average age: 74 years (range 54 to 88)
Sex: 60% women
Inclusion criteria:
• 50+ years old• Written informed consent• Exudative AMD with subfoveal involvement and signs of ARM in the fellow eye• CNV 6+ disc diameters in size• Visual acuity 20/320 or better in study eye• Symptoms for six months or less.
Exclusion criteria:
• Ocular disease that could compromise the visual acuity in the study eye• Haemorrhage• Previous macular photocoagulation or PDT• History of antiangiogenic drugs.
Interventions Intervention: (n=101)
• External beam radiation therapy (8 fraction of 2 Gy)• Duration: 10 days
Comparator: (n=104)
• Sham irradiation (8 fractions of 0Gy)
Outcomes Primary outcome:
• Change in visual acuity between baseline and 12 months (logMAR, ETDRS)
Secondary: NR
Reported:
• Safety
Follow-up: 6 and 12 months
Notes Full study name: The Radiation Therapy for Age-related Macular Degeneration (RAD) Study
Date conducted: February 1996 to October 1997
Sources of funding: Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany (grant # Vo 437/3-1), and
by the State of Baden-Wu¨rttemberg, Heidelberg, Germany (grant # 88/94).
Declaration of interest: NR
Trial id: NR
Risk of bias
RAD 1999  (Continued)
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The randomization list was compiled generating random numbers us-
ing the statistical analysis system SAS, version 6.12." Page 2240
Allocation concealment
(selection bias)
Low risk Quote: "To ensure concealment, external randomization by telephone was
performed by the Biostatistics and Data Centre, Heidelberg, Germany." Page
2240
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
Low risk Quote:"Patients in the placebo group were similarly planed and placed at the
linear accelerator for 8 fractions with a dose of 8 x 0Gy. The machine noise dur-
ing irradiation was simulated, and the technicians were instructed not to in-
form the patient about the mode of treatment. The sham treatment method
was spread out over an identical time course as the radiation treatment." Page
2240
Quote "To ensure masking of patients and ophthalmologists, only the respec-
tive departments of radiation therapy were informed about treatment alloca-
tion." Page 2240
Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Low risk Quote "To ensure masking of patients and ophthalmologists, only the respec-
tive departments of radiation therapy were informed about treatment alloca-
tion." Page 2240
 
Quote: "All angiograms were read by reviewers masked to treatment assign-
ments." Page 2240
Blinding of outcome as-
sessment (detection bias)
Visual acuity
Low risk Quote: "Patients in the placebo group were similarly planed and placed at the
linear accelerator for 8 fractions with a dose of 8 x 0Gy. The machine noise dur-
ing irradiation was simulated, and the technicians were instructed not to in-
form the patient about the mode of treatment. The sham treatment method
was spread out over an identical time course as the radiation treatment." Page
2240
Quote: "To ensure masking of patients and ophthalmologists, only the respec-
tive departments of radiation therapy were informed about treatment alloca-
tion." Page 2240
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
Low risk Quote: "All angiograms were read by reviewers masked to treatment assign-
ments." Page 2240
Incomplete outcome data
(attrition bias)
All outcomes
Low risk Judgement comment: radiation group 88/101 (87.1%) completed study 7 of
these protocol deviations. Sham therapy group 95/104 (91.3%) completed
study. Detailed information given on loss to follow-up. Page 2241, figure 1.
Selective reporting (re-
porting bias)
Unclear risk Judgement comment: no access to study protocol or trial registry entry.
RAD 1999  (Continued)
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One eye per person, unclear how selected
Participants Country: UK
Number of participants (eyes) randomised: 203 (203)
Number of participants (eyes) excluded after randomisation: 4 (4)
Number of participants (eyes) analysed: 184 (at 12 months) 174 (at 24 months)
Average age: 75 years (range NR)
Sex: 57% women
Inclusion criteria:
• Aged 60+• Subfoveal CNV
Visual acuity 20/200 or better in study eye.
Exclusion criteria:
• Inability to give informed consent• Late leakage of indeterminate origin• Blood under geometric centre of the fovea• Other ocular disease• Diabetes• Other trials• Prior radiotherapy
Interventions Intervention: (n=99)*
• External beam radiation therapy (6 fractions of 2 Gy)• Duration: 6 consecutive working days
Comparator: (n=100)*
• Observation
Duration:
*One control participant treated and included in intervention group; 4 protocol violations excluded.
Outcomes Primary outcome:
• Loss of visual acuity at 12 and 24 months (logMAR, EDTRS)
Secondary:
• Near visual acuity (Bailey-Lovie chart)• Contrast sensitivity• Complications• Quality of life
Follow-up: 3, 6, 12 and 24 months
Notes Full study name: Subfoveal Radiotherapy Study (SFRADS)
Date conducted: November 1995 to July 1998
Sources of funding: Project grant G9404235 from Medical Research Council of the UIK.
Declaration of interest: NR
SFRADS 2002  (Continued)
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Trial id: ISRCTN84737434
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "To ensure balance within each of the 3 centers, the randomization was
blocked." Hart et al, page 1031.
Allocation concealment
(selection bias)
Low risk Quote: "The randomization code was kept at the coordinating center (Belfast)
and released by telephone on receipt of patient details."Hart et al, page
1030/1031.
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
High risk Quote: "The optometrists who undertook visual assessments were unaware of
the treatment status of the patients; however, neither the treating physicians
nor the patients were masked". Hart et al, page 1030
Judgement comment: participants and personnel were not masked which
may have affected the visual acuity outcome.
Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Unclear risk Judgement comment: outcome not reported so far.
Blinding of outcome as-
sessment (detection bias)
Visual acuity
High risk Quote: "The optometrists who undertook visual assessments were unaware of
the treatment status of the patients; however, neither the treating physicians
nor the patients were masked". Hart et al, page 1030
Judgement comment: although visual acuity assessment was masked to treat-
ment group, physicians and patients were not. It is possible that an individ-
ual’s performance on the visual acuity test could be influenced by their per-
ceptions as to which treatment they received.
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
Unclear risk Judgement comment: outcome not reported so far.
Incomplete outcome data
(attrition bias)
All outcomes
Unclear risk Judgement comment: 101 allocated to treatment 102 to observation. 93/101
and 91/100 seen at 12 months. Not very good documentation for reasons for
no follow-up.
Selective reporting (re-
porting bias)
Low risk Judgement comment: trials registry outcomes reported
SFRADS 2002  (Continued)
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One eye per person, unclear how selected
Participants Country: Switzerland.
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Number of participants (eyes) randomised: 161 (161)
Number of participants (eyes) excluded after randomisation: NR
Number of participants (eyes) analysed: 150 (6 months) 139 (12 months) 137 (18 months)
Average age: 75 years (range NR)
Sex: 58% women
Inclusion criteria:
• Subfoveal CNV in AMD• Rapid worsening of visual acuity, a central scotoma, or metamorphopsia
Exclusion criteria:
• Foveal haemorrhage• Severe haemorrhage or serous PED impeding measurement of CNV• Preexisting ocular disease (glaucoma, severe myopia, diabetic retinopathy).
Interventions Intervention 1: (n=52)
• External beam radiation therapy (4 fractions of 4 Gy)
Intervention 2: (n=57)
• External beam radiation therapy (4 fractions of 2 Gy)
Comparator: (n=52)
• External beam radiation therapy (4 fractions of 0.25 Gy)
Duration: 4 days.
Outcomes Primary: NR
Secondary: NR
Reported:
• BCVA (logMAR)• Reading ability• Radiation-associated side effects (ocular irritation, conjunctivitis, cataract, radiation retinopathy, ra-
diation optic neuropathy)
Follow-up: 6, 12 and 18 months
Notes Date conducted: November 1994 to February 1999
Sources of funding: NR
Declaration of interest: NR
Trial id: NR
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The patients were stratified in four different subgroups according to
the CNV type, size and duration of the symptoms" Page 522
Quote: "According to the stratification, patients were randomized and treated
in the Department of Radiation-Oncology." Page 522
Valmaggia 2002  (Continued)
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Judgement comment: not clear how the allocation schedule was generated. 
Allocation concealment
(selection bias)
Low risk Quote: "The collaborators in the Department of Ophthalmology and patients
were not aware of the applied radiation dose. Colleagues in the Department of
Radiation-Oncology were only informed about the eye to be treated and the
stratification code." Page 522.
 
Blinding of participants
and personnel (perfor-
mance bias)
Visual acuity
Low risk Quote: "The collaborators in the Department of Ophthalmology and patients
were not aware of the applied radiation dose." Page 522
Blinding of participants
and personnel (perfor-
mance bias)
Lesion size on fluorescein
angiography
Low risk Quote: "The collaborators in the Department of Ophthalmology and patients
were not aware of the applied radiation dose." Page 522
Blinding of outcome as-
sessment (detection bias)
Visual acuity
Low risk Quote: "The collaborators in the Department of Ophthalmology and patients
were not aware of the applied radiation dose." Page 522
Blinding of outcome as-
sessment (detection bias)
Lesion size on fluorescein
angiography
Low risk Quote: "The collaborators in the Department of Ophthalmology and patients
were not aware of the applied radiation dose." Page 522
Incomplete outcome data
(attrition bias)
All outcomes
Unclear risk Judgement comment: control group 44/52 (85%) seen at 12 months; 8Gy
group 52/57 (91%) seen at 12 months; 16Gy group 43 (83%) seen at 12 months.
Page 524, table 2.
Selective reporting (re-
porting bias)
Unclear risk Judgement comment: no access to study protocol or trial registry entry.
Valmaggia 2002  (Continued)
AMD: age-related macular degeneration
ARM: age-related maculopathy
CNV: choroidal neovascularisation
CRT: central retinal thickness
ETDRS: Early Treatment of Diabetic Retinopathy Study
FFA: fundus fluorescein angiography
Gy: gray
NR: Not reported
OCT: optical coherence tomography
PDT: photodynamic therapy
PED: pigment epithelial detachment
PRN: pro re nata
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Avila 2009 Not a randomised controlled trial.
Barak 2005 No control group.
Bergink 1995 Treatment groups probably not randomly allocated.
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Study Reason for exclusion
Brown 1997 Treatment groups allocated sequentially.
Churei 2004 Treatment groups not randomly allocated.
Eter 2001 One eye treated and fellow eye served as a control. Unclear whether first eye treated randomly.
Friedrichsen 1996 Abstract only reporting two different doses of radiotherapy
Heier 2008 Avastin but not radiotherapy allocated randomly.
Honjo 1997 Treatment groups probably not randomly allocated.
Jackson 2012 Not a report of a randomised controlled trial
Mandai 1998 Treatment groups probably not randomly allocated.
Mandai 2000 Retrospective study - groups not allocated randomly.
Marcus 2004 Non-randomised dose escalation study.
Matsuhashi 1996 Treatment groups not allocated randomly.
Matsuhashi 2000 Treatment groups not allocated randomly. Control group consisted of people who had refused ra-
diation or laser treatment.
NCT01833325 Single group assignment
Postgens 1997 Retrospective study - groups not allocated randomly.
Reichel 2007 All participants received radiotherapy, different regimen for anti-VEGF compared.
Saric 2001 Control group consisted of participants who had refused treatment.
Taniguchi 1996 Treatment and control groups probably not randomly allocated.
Tholen 2000 This study initially began as an RCT but the trial was stopped because of radiogenic complications
in the high dose group (36 Gy). The study was continued as a non-randomised study and the re-
ports did not distinguish randomised and non-randomised comparisons.
Zambarakji 2006 No untreated control group.
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Stereotactic Radiotherapy for Wet AMD (STAR)
Methods Parallel group RCT
Participants Country: UK (10 hospitals)
Estimated number of participants: 411
Ages: 50 years and above
STAR (NCT02243878) 
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<from clinicaltrials.gov>
Inclusion Criteria
1. Participants must have neovascular AMD in the study eye, for which they have received at least 3 prior
intravitreal injections of either bevacizumab (Avastin), aflibercept (Eylea), ranibizumab (Lucentis),
or pegaptanib (Macugen).
2. Participants must have received an anti-VEGF injection in the study eye within 3 months prior to en-
rolment.
3. Participants must require treatment with anti-VEGF therapy at the time of enrolment, due to OCT
evidence of subretinal fluid and/or cystoid macular oedema, and a macular volume that is greater
than the 95th percentile of normal for the SD-OCT machines used in the investigational sites.
4. Participants must be at least 50 years of age.
Exclusion Criteria
1. Disciform scarring that involves the fovea, in the study eye.
2. Geographic atrophy that involves the fovea, or an area of geographic atrophy that is more than 500
microns in greatest diameter, immediately adjacent to the fovea, in the study eye.
3. Visual acuity worse than 6/96 (24 ETDRS letters) in the study eye.
4. Lesion size greater than 4 mm in greatest linear dimension, or greater than 2 mm from the centre of
the fovea to the furthest point on the lesion perimeter.
5. Distance from the centre of the fovea to the nearest edge of the optic disc less than 3 mm in the study
eye (this distance is confirmed by the Oraya SRT device software immediately prior to treatment).
6. An axial length of less than 20 mm, or greater than 26 mm, in the study eye.
7. Contraindication or sensitivity to contact lens application, including recurrent corneal erosions, in
the study eye.
8. Type 1 or Type 2 diabetes mellitus.
9. Retinopathy in the study eye.
10.Prior or current therapies in the study eye for age-related macular degeneration, other than an-
ti-VEGF agents, including submacular surgery, subfoveal thermal laser photocoagulation, photody-
namic therapy (PDT), or transpupillary thermotherapy (TTT).
11.Presence of an intravitreal device in the study eye.
12.Previous radiation therapy to the study eye, head, or neck with the exception of radio-iodine treat-
ment for hyperthyroidism, epimacular brachytherapy to the non-study eye, or Oraya SRT to the non-
study eye.
13.Inadequate pupillary dilation or significant media opacities in the study eye, including cataract,
which may interfere with visual acuity testing, the clinical evaluation of the posterior segment, or
fundus imaging.
14.Likely to need cataract surgery in the study eye, within two years of enrolment.
15.Study eyes with CNV due to causes other than AMD, including presumed ocular histoplasmosis syn-
drome (POH), angioid streaks, multifocal choroiditis, choroidal rupture, and pathological myopia
(greater than 8 Dioptres spherical equivalent). Participants with retinal angiomatous proliferation
(RAP) or idiopathic polypoidal choroidal vasculopathy (IPCV) are not excluded.
16.Known allergy to intravenous fluorescein, ICG or intravitreal ranibizumab.
17.Intraocular surgery or laser-assisted in situ keratomileusis (LASIK) in the study eye within 12 weeks
prior to enrolment.
18.Prior pars plana vitrectomy in the study eye.
19.Current participation in another interventional clinical trial, or participation in such a clinical trial
within the last six months.
20.Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of the trial.
21.Women who are pregnant at the time of radiotherapy.
22.Participants with an implantable cardioverter defibrillator (ICD) or pacemaker implant (or any im-
planted device) where the device labelling specifically contraindicates patients undergoing X-ray.
STAR (NCT02243878)  (Continued)
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23.Any other condition, which in the judgment of the investigator, would prevent the participant from
granting informed consent or completing the study, such as dementia, and mental illness (including
generalized anxiety disorder and claustrophobia)
Interventions Intervention:
• Stereotactic radiotherapy (16 Gy)• Intravitreal injections of 0.5 mg ranibizumab (1 dose at baseline, then as needed up to monthly,
if predefined retreatment criteria are met)
Comparator:
• Sham stereotactic radiotherapy (0 Gy)• Intravitreal injections of 0.5 mg ranibizumab (1 dose at baseline, then as needed up to monthly,
if predefined retreatment criteria are met)
Outcomes <from clnicaltrials.gov>
• Primary Outcome Measures: Number of as required (prn) ranibizumab injections during the first 24
months• Secondary Outcome Measures: Mean Early Treatment of Diabetic Retinopathy Study (ETDRS) visual
acuity (VA) at 24 months.
Starting date December 2014 to October 2022
Contact information Timothy Jackson t.jackson1@nhs.net
Notes www.starstudy.org.uk
www.clinicaltrials.gov/ct2/show/NCT02243878
www.isrctn.com/ISRCTN12884465
STAR (NCT02243878)  (Continued)
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Comparison 1.   Radiation therapy versus control
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.1 Loss of 3 or more lines best-corrected
visual acuity lost at 12 months
8 811 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.64, 1.04]
1.2 Three or more lines visual acuity lost
at 24 months
4 654 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.63, 0.97]
1.3 Change in BCVA at 12 months 10 883 Mean Difference (IV, Random, 95%
CI)
-0.10 [-0.17, -0.03]
1.3.1 Change in visual acuity 7 771 Mean Difference (IV, Random, 95%
CI)
-0.09 [-0.16, -0.02]
1.3.2 Final value 3 112 Mean Difference (IV, Random, 95%
CI)
-0.17 [-0.41, 0.08]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.4 Change in BCVA at 24 months 6 516 Mean Difference (IV, Random, 95%
CI)
-0.09 [-0.15, -0.03]
1.5 Change in contrast sensitivity 2   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.5.1 12 months 2 267 Mean Difference (IV, Fixed, 95% CI) 0.15 [0.05, 0.25]
1.5.2 24 months 2 257 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.00, 0.22]
1.6 Contrast sensitivity raw data 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.6.1 12 months 1 83 Mean Difference (IV, Fixed, 95% CI) -0.22 [-0.38, -0.06]
1.6.2 24 months 1 82 Mean Difference (IV, Fixed, 95% CI) -0.22 [-0.41, -0.03]
 
 
Analysis 1.1.   Comparison 1: Radiation therapy versus control, Outcome
1: Loss of 3 or more lines best-corrected visual acuity lost at 12 months
Study or Subgroup
AMDRT 2004
Bergink 1998
Char 1999
Jaakkola 2005 (1)
Marcus 2001
RAD 1999
SFRADS 2002
Valmaggia 2002
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.07; Chi² = 20.41, df = 7 (P = 0.005); I² = 66%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
Radiotherapy
Events
13
11
4
21
30
45
53
20
197
Total
31
34
14
43
37
88
93
95
435
Control
Events
15
15
10
22
22
50
52
22
208
Total
31
29
13
41
33
95
90
44
376
Weight
10.2%
9.3%
5.7%
13.1%
16.4%
16.6%
17.3%
11.5%
100.0%
Risk Ratio
M-H, Random, 95% CI
0.87 [0.50 , 1.50]
0.63 [0.34 , 1.14]
0.37 [0.15 , 0.90]
0.91 [0.60 , 1.38]
1.22 [0.91 , 1.62]
0.97 [0.73 , 1.28]
0.99 [0.77 , 1.27]
0.42 [0.26 , 0.69]
0.82 [0.64 , 1.04]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours radiotherapy Favours control
Footnotes
(1) Brachytherapy
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Analysis 1.2.   Comparison 1: Radiation therapy versus control,
Outcome 2: Three or more lines visual acuity lost at 24 months
Study or Subgroup
Jaakkola 2005
Kobayashi 2000 (1)
SFRADS 2002
Valmaggia 2002
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.03; Chi² = 10.93, df = 3 (P = 0.01); I² = 73%
Test for overall effect: Z = 2.26 (P = 0.02)
Test for subgroup differences: Not applicable
Radiotherapy
Events
30
23
61
90
204
Total
41
45
87
181
354
Control
Events
29
35
71
94
229
Total
41
40
88
131
300
Weight
22.6%
20.3%
28.9%
28.2%
100.0%
Risk Ratio
M-H, Random, 95% CI
1.03 [0.79 , 1.36]
0.58 [0.43 , 0.80]
0.87 [0.73 , 1.03]
0.69 [0.58 , 0.83]
0.78 [0.63 , 0.97]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours radiotherapy Favours control
Footnotes
(1) Brachytherapy
 
 
Analysis 1.3.   Comparison 1: Radiation therapy versus control, Outcome 3: Change in BCVA at 12 months
Study or Subgroup
1.3.1 Change in visual acuity
Char 1999
Jaakkola 2005 (1)
Kobayashi 2000
Marcus 2001
RAD 1999
SFRADS 2002
Valmaggia 2002
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 11.16, df = 6 (P = 0.08); I² = 46%
Test for overall effect: Z = 2.45 (P = 0.01)
1.3.2 Final value
AMDLRTSG 2003
Anders 1998
Ciulla 2002
Subtotal (95% CI)
Heterogeneity: Tau² = 0.03; Chi² = 6.47, df = 2 (P = 0.04); I² = 69%
Test for overall effect: Z = 1.33 (P = 0.18)
Total (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 17.64, df = 9 (P = 0.04); I² = 49%
Test for overall effect: Z = 2.77 (P = 0.006)
Test for subgroup differences: Chi² = 0.35, df = 1 (P = 0.55), I² = 0%
MD
-0.32
-0.137
-0.196
0.075
-0.02
-0.06
-0.1213
-0.287
0.02
-0.33
SE
0.1696
0.077816
0.063467
0.079
0.063484
0.055
0.0579
0.1195
0.0753
0.1883
Radiation therapy
Total
14
42
45
37
88
93
95
414
30
19
16
65
479
Control
Total
13
41
40
33
95
91
44
357
21
18
8
47
404
Weight
3.7%
10.8%
13.0%
10.6%
13.0%
14.5%
14.0%
79.5%
6.3%
11.1%
3.1%
20.5%
100.0%
Mean Difference
IV, Random, 95% CI
-0.32 [-0.65 , 0.01]
-0.14 [-0.29 , 0.02]
-0.20 [-0.32 , -0.07]
0.07 [-0.08 , 0.23]
-0.02 [-0.14 , 0.10]
-0.06 [-0.17 , 0.05]
-0.12 [-0.23 , -0.01]
-0.09 [-0.16 , -0.02]
-0.29 [-0.52 , -0.05]
0.02 [-0.13 , 0.17]
-0.33 [-0.70 , 0.04]
-0.17 [-0.41 , 0.08]
-0.10 [-0.17 , -0.03]
Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours radiation therapy Favours control
Footnotes
(1) Brachytherapy
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Analysis 1.4.   Comparison 1: Radiation therapy versus control, Outcome 4: Change in BCVA at 24 months
Study or Subgroup
Anders 1998
Ciulla 2002
Jaakkola 2005
Kobayashi 2000
SFRADS 2002
Valmaggia 2002
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.69, df = 5 (P = 0.75); I² = 0%
Test for overall effect: Z = 2.92 (P = 0.003)
Test for subgroup differences: Not applicable
MD
0.01
-0.11
-0.032
-0.134
-0.091
-0.1409
SE
0.0885
0.1509
0.0875
0.0724
0.056
0.0666
Radiation therapy
Total
14
6
41
45
87
94
287
Control
Total
12
5
41
40
88
43
229
Weight
12.3%
4.2%
12.6%
18.4%
30.7%
21.7%
100.0%
Mean Difference
IV, Random, 95% CI
0.01 [-0.16 , 0.18]
-0.11 [-0.41 , 0.19]
-0.03 [-0.20 , 0.14]
-0.13 [-0.28 , 0.01]
-0.09 [-0.20 , 0.02]
-0.14 [-0.27 , -0.01]
-0.09 [-0.15 , -0.03]
Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours radiation therapy Favours control
 
 
Analysis 1.5.   Comparison 1: Radiation therapy versus control, Outcome 5: Change in contrast sensitivity
Study or Subgroup
1.5.1 12 months
Jaakkola 2005
SFRADS 2002
Subtotal (95% CI)
Heterogeneity: Chi² = 1.27, df = 1 (P = 0.26); I² = 21%
Test for overall effect: Z = 2.89 (P = 0.004)
1.5.2 24 months
Jaakkola 2005
SFRADS 2002
Subtotal (95% CI)
Heterogeneity: Chi² = 2.11, df = 1 (P = 0.15); I² = 53%
Test for overall effect: Z = 1.98 (P = 0.05)
Test for subgroup differences: Chi² = 0.27, df = 1 (P = 0.60), I² = 0%
MD
0.22
0.102
0.22
0.052
SE
0.08235
0.065
0.09443
0.067
Radiation therapy
Total
42
93
135
41
87
128
Control
Total
41
91
132
41
88
129
Weight
38.4%
61.6%
100.0%
33.5%
66.5%
100.0%
Mean Difference
IV, Fixed, 95% CI
0.22 [0.06 , 0.38]
0.10 [-0.03 , 0.23]
0.15 [0.05 , 0.25]
0.22 [0.03 , 0.41]
0.05 [-0.08 , 0.18]
0.11 [0.00 , 0.22]
Mean Difference
IV, Fixed, 95% CI
-1 -0.5 0 0.5 1
Favours control Favours radiation therapy
 
 
Analysis 1.6.   Comparison 1: Radiation therapy versus control, Outcome 6: Contrast sensitivity raw data
Study or Subgroup
1.6.1 12 months
Jaakkola 2005 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.67 (P = 0.008)
1.6.2 24 months
Jaakkola 2005 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.33 (P = 0.02)
Test for subgroup differences: Chi² = 0.00, df = 1 (P = 1.00), I² = 0%
Radiation
Mean [log units]
0.17
0.26
SD [log units]
0.37
0.34
Total
42
42
41
41
Control
Mean [log units]
0.39
0.48
SD [log units]
0.38
0.5
Total
41
41
41
41
Weight
100.0%
100.0%
100.0%
100.0%
Mean Difference
IV, Fixed, 95% CI [log units]
-0.22 [-0.38 , -0.06]
-0.22 [-0.38 , -0.06]
-0.22 [-0.41 , -0.03]
-0.22 [-0.41 , -0.03]
Mean Difference
IV, Fixed, 95% CI [log units]
-1 -0.5 0 0.5 1
Favours radiation therapy Favours control
Footnotes
(1) Change (decrease) in mean contrast sensitivity from baseline (nb Mann Whitney U test)
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Comparison 2.   Radiation therapy with anti-VEGF versus anti-VEGF alone
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2.1 Three or more lines visual acuity
lost at 12 months
3 1050 Risk Ratio (M-H, Fixed, 95% CI) 2.11 [1.40, 3.17]
2.1.1 Epimacular brachytherapy 2 820 Risk Ratio (M-H, Fixed, 95% CI) 2.36 [1.49, 3.74]
2.1.2 Stereotactic radiotherapy 1 230 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.50, 3.11]
2.2 Three or more lines visual acuity
lost at 24 months
2 820 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [1.68, 3.39]
2.3 Change in BCVA at 12 months 4 1072 Mean Difference (IV, Random, 95% CI) 0.05 [-0.03, 0.13]
2.3.1 Epimacular brachytherapy 2 820 Mean Difference (IV, Random, 95% CI) 0.10 [0.05, 0.15]
2.3.2 External beam radiotherapy 2 252 Mean Difference (IV, Random, 95% CI) -0.03 [-0.09, 0.03]
2.4 Change in BCVA at 24 months 2 819 Mean Difference (IV, Random, 95% CI) 0.17 [0.11, 0.23]
 
 
Analysis 2.1.   Comparison 2: Radiation therapy with anti-VEGF versus anti-
VEGF alone, Outcome 1: Three or more lines visual acuity lost at 12 months
Study or Subgroup
2.1.1 Epimacular brachytherapy
CABERNET 2013 (1)
MERLOT 2016 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 0.10, df = 1 (P = 0.75); I² = 0%
Test for overall effect: Z = 3.66 (P = 0.0003)
2.1.2 Stereotactic radiotherapy
INTREPID 2013 (2)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 1.59, df = 2 (P = 0.45); I² = 0%
Test for overall effect: Z = 3.57 (P = 0.0004)
Test for subgroup differences: Chi² = 1.49, df = 1 (P = 0.22), I² = 33.1%
Radiotherapy and anti-VEGF
Events
54
40
94
14
14
108
Total
302
244
546
150
150
696
Anti-VEGF alone
Events
11
9
20
6
6
26
Total
155
119
274
80
80
354
Weight
42.2%
35.1%
77.3%
22.7%
22.7%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
2.52 [1.36 , 4.68]
2.17 [1.09 , 4.32]
2.36 [1.49 , 3.74]
1.24 [0.50 , 3.11]
1.24 [0.50 , 3.11]
2.11 [1.40 , 3.17]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours radiotherapy Favours control
Footnotes
(1) Epimacular brachytherapy
(2) Stereotactic radiotherapy
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Analysis 2.2.   Comparison 2: Radiation therapy with anti-VEGF versus anti-
VEGF alone, Outcome 2: Three or more lines visual acuity lost at 24 months
Study or Subgroup
CABERNET 2013 (1)
MERLOT 2016 (1)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 0.16, df = 1 (P = 0.69); I² = 0%
Test for overall effect: Z = 4.85 (P < 0.00001)
Test for subgroup differences: Not applicable
Radiotherapy and anti-VEGF
Events
69
84
153
Total
302
244
546
Anti-VEGF alone
Events
16
16
32
Total
155
119
274
Weight
49.6%
50.4%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
2.21 [1.33 , 3.68]
2.56 [1.57 , 4.17]
2.39 [1.68 , 3.39]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours radiotherapy Favours control
Footnotes
(1) Epimacular brachytherapy
 
 
Analysis 2.3.   Comparison 2: Radiation therapy with anti-VEGF
versus anti-VEGF alone, Outcome 3: Change in BCVA at 12 months
Study or Subgroup
2.3.1 Epimacular brachytherapy
CABERNET 2013
MERLOT 2016
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.99, df = 1 (P = 0.16); I² = 50%
Test for overall effect: Z = 3.90 (P < 0.0001)
2.3.2 External beam radiotherapy
INTREPID 2013 (1)
Osmanovic 2017
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.98); I² = 0%
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 16.11, df = 3 (P = 0.001); I² = 81%
Test for overall effect: Z = 1.24 (P = 0.22)
Test for subgroup differences: Chi² = 11.51, df = 1 (P = 0.0007), I² = 91.3%
Radiotherapy and anti-VEGF
Mean [logMAR]
0.01
0.096
-0.0012
-0.175
SD [logMAR]
0.326
0.216
0.1911
0.25
Total
302
244
546
150
14
164
710
Anti-VEGF alone
Mean [logMAR]
-0.12
0.018
0.0314
-0.14
SD [logMAR]
0.278
0.194
0.238
0.25
Total
155
119
274
80
8
88
362
Weight
29.6%
31.6%
61.2%
29.1%
9.7%
38.8%
100.0%
Mean Difference
IV, Random, 95% CI [logMAR]
0.13 [0.07 , 0.19]
0.08 [0.03 , 0.12]
0.10 [0.05 , 0.15]
-0.03 [-0.09 , 0.03]
-0.03 [-0.25 , 0.18]
-0.03 [-0.09 , 0.03]
0.05 [-0.03 , 0.13]
Mean Difference
IV, Random, 95% CI [logMAR]
-1 -0.5 0 0.5 1
Favours radiotherapy Favours control
Footnotes
(1) Stereotactic
 
 
Analysis 2.4.   Comparison 2: Radiation therapy with anti-VEGF
versus anti-VEGF alone, Outcome 4: Change in BCVA at 24 months
Study or Subgroup
CABERNET 2013 (1)
MERLOT 2016 (1)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.72, df = 1 (P = 0.19); I² = 42%
Test for overall effect: Z = 5.89 (P < 0.00001)
Test for subgroup differences: Not applicable
Radiotherapy and anti-VEGF
Mean [logMAR]
0.05
0.224
SD [logMAR]
0.328
0.314
Total
302
243
545
Anti-VEGF alone
Mean [logMAR]
-0.088
0.028
SD [logMAR]
0.35
0.218
Total
155
119
274
Weight
44.9%
55.1%
100.0%
Mean Difference
IV, Random, 95% CI [logMAR]
0.14 [0.07 , 0.20]
0.20 [0.14 , 0.25]
0.17 [0.11 , 0.23]
Mean Difference
IV, Random, 95% CI [logMAR]
-1 -0.5 0 0.5 1
Favours radiotherapy Favours control
Footnotes
(1) Epimacular brachytherapy
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  Review edi-
tion study
first included
Study name Country Funding Number
of peo-
ple ran-
domised
Num-
ber of
eyes ran-
domised
Note Aver-
age age
(years)
% female
1 2010 AMDLTRSG 2003 Japan NR 69 69 Analysed 72 30
2 2010 AMDRT 2004 US NIH 88 88   77 58
3 2004 Anders 1998 Germany NR 76 76 unclear
how many
eyes
77 67
4 2004 Bergink 1998 The Netherlands NR 74 74   75 56
5 2019 CABERNET 2013 US, Europe, Is-
rael, South Amer-
ica
Manufac-
turer
494 494   77 68
6 2004 Char 1999 US NGO 27 27   76 52
7 2004 Ciulla 2002 US NGO 37 37 unclear
how many
eyes
71 38
8 2004 Eter 2002 Germany NR 45 45   74 57
9 2019 INTREPID 2013 Europe Manufac-
turer
230 230   74 69
10 2010 Jaakkola 2005 Finland NGO 86 88   76 60
11 2004 Kacperek 2001 UK NR 58 58 unclear
how many
eyes
76 61
12 2004 Kobayashi 2000 Japan NGO 101 101   72 64
13 2004 Marcus 2001 US NGO 83 83   76 61
14 2019 MERLOT UK Manufac-
turer
363 363   77 60
Table 1.   Study characteristics 
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15 2019 Osmanovic 2017 US NGO 30 30   77 59
16 2004 RAD 1999 Germany GOV/NGO 205 205   74 60
17 2004 SFRADS 2002 UK GOV 203 203   75 57
18 2004 Valmaggia 2002 Switzerland NR 161 161   75 58
  Total       2430 2432    Median 76  Median 60
 
Table 1.   Study characteristics  (Continued)
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  Study % classic % occult % mixed
1 AMDLRTSG 2003 NR
 
2 AMDRT 2004 18 (predominantly classic) 21 61 (min-
imally
classic)
3 Anders 1998 NR
 
4 Bergink 1998 52 24 25
5 CABERNET 2013 39 (predominantly classic) 35 25
6 Char 1999 48 52  
7 Ciulla 2002 46 14 39
8 Eter 2002 37 Mixed/occult = 63.0
9 INTREPID 2013 NR
 
 
10 Jaakkola 2005 40 ("a classic component") 52 ("occult no
classic")
 
11 Kacperek 2001 NR
12 Kobayashi 2000 51 13 21
13 Marcus 2001 12 42 43
14 MERLOT 2016 12 75 12
15 Osmanovic 2017 50 50  
16 RAD 1999 38 62  
17 SFRADS 2002 52 2 43
18 Valmaggia 2002 57 43  
Table 2.   Type of choroidal neovascularisation 
NR: Not reported
 
 
Study Total
dose (Gy)
Number
of frac-
tions
Control Comments
Table 3.   Characteristics of the intervention and comparator 
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Trials of external beam radiotherapy  
INTREPID
2013
24 and 16 1 Sham radiotherapy,
ranibizumab (0.5mg and PRN)
Stereotactic radiotherapy; two arms receiving differ-
ent radiation dose; all groups received ranibizumab
(0.5mg and PRN)
Osmanovic
2017
24 and 16 2 Sham radiotherapy,
ranibizumab or bevacizumab
Two arms receiving different radiation dose; all
groups received ranibizumab or bevacizumab
Bergink 1998 24 4 Observation  
AMDRT 2004 20 5 Observation and sham radio-
therapy
 
Eter 2002 20 10 Observation  
Kobayashi
2000
20 10 Observation  
AMDLRTSG
2003
20 10 Observation  
Kacperek 2001 18 4 Observation  
Ciulla 2002 16 2 Sham irradiation  
RAD 1999 16 8 Sham irradiation (0 Gy)  
Marcus 2001 14 7 Sham irradiation  
SFRADS 2002 12 6 Observation  
Anders 1998 12 6 Observation  
Valmaggia
2002
8 4 Low dose irradiation (1 Gy)  
Char 1999 7.5 1 Observation  
Trials of brachytherapy (radiation source placed near the lesion)  
CABERNET
2013
24 1 Ranibizumab (0.5mg) 3 injec-
tions, over 3 months followed
by quarterly injections
Epimacular brachytherapy; pars plana vitrectomy and
placing of strontium 90/yttrium 90 applicator over
AMD lesion. Intervention group also received 2 intrav-
itreal injections of 0.5mg ranibizumab, one at the end
of surgery and one 30 days later
MERLOT 2016
 
24 1 Ongoing PRN ranibizumab
(0.5mg)
Epimacular brachytherapy; pars plana vitrectomy
and placing of strontium 90 probe over AMD lesion to
deliver required dose. All participants received PRN
ranibizumab (0.5mg)
Jaakkola 2005 12 to 15 1 Observation Plaque brachytherapy. One strontium 90 plaque de-
livered a dose of 15 Gy at a depth of 1.75 mm for 54
minutes but as this took too long another plaque was
used which delivered a dose of 12.6 Gy at 4 mm depth
for 11 minutes
Table 3.   Characteristics of the intervention and comparator  (Continued)
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PRN: pro re nata
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Radiotherapy ControlSubgroup
n N n N
Risk ratio CI Start CI End I2 Test for inter-
action (P-val-
ue)
Num-
ber of
stud-
ies
All studies 197 435 208 376 0.82 0.64 1.04 66%   8
≤14Gy 107 239 106 180 0.73 0.44 1.20 84% 4Dose
>14Gy 90 196 102 196 0.90 0.73 1.10 0%
0.442
4
Classic <50% 113 213 119 213 0.94 0.73 1.21 47% 5Type of CNV
Classic 50% + 84 222 89 163 0.66 0.37 1.16 80%
0.261
3
No sham irradiation 102 215 114 204 0.83 0.64 1.07 32% 5Sham irradiation in
the control group
Sham irradiation 95 220 94 172 0.82 0.49 1.39 86%
0.982
3
Table 4.   Subgroup analyses: three or more lines best-corrected visual acuity lost at 12 months 
CI: confidence intervals CNV: choroidal neovascularisation
 
 
Subgroup Radio-
therapy N
Control N Mean difference CI Start CI End I2 Test for in-
teraction P
value
Number
of studies
All studies   479 404 -0.10 -0.17 -0.03 49%   10
≤14Gy 258 199 -0.05 -0.14 0.04 46% 5Dose
>14Gy 221 205 -0.15 -0.25 -0.05 42%
0.134
5
Classic <50% 197 190 -0.09 -0.21 0.04 54% 5
Classic 50%+ 233 175 -0.12 -0.20 -0.04 24% 3
Type of CNV
% classic not report-
ed
49 39 -0.12 -0.42 0.18 79%
0.901
2
Sham irradiation in
the control group
No sham irradiation 243 224 -0.13 -0.22 -0.04 47% 0.321 6
Table 5.   Subgroup analyses: change in best-corrected visual acuity at 12 months 
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Sham irradiation 236 180 -0.05 -0.17 0.06 53% 4
Table 5.   Subgroup analyses: change in best-corrected visual acuity at 12 months  (Continued)
CI: confidence intervals CNV: choroidal neovascularisation
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  Study Number of
eyes ran-
domised
Report
1 AMDLRTSG
2003
69 No comment on adverse effects in the report
2 AMDRT 2004 88 "Adverse events were infrequent.By 12 months, one treated patient devel-
oped multiple cotton wool spots and retinal nonperfusion adjacent to the
disc, possibly indicating radiation retinopathy. Visual acuity in this eye was
20/80 at baseline and 20/80 at 12 months. There were five deaths among AM-
DRT patients: four of which occurred among patients who did not receive
EBR. Cataract surgery was performed on two patients, one in each treatment
group. Six patients reported ocular dryness; four had not received EBR and
two had received EBR"
3 Anders 1998 76 Subretinal haemorrhage in 3 cases in both treatment and control groups.
No other complications reported.
4 Bergink 1998 74 The prevalence of retinal abnormalities high in both treatment and control
groups (72% and 71% respectively) but unlikely to be attributable to radia-
tion.
5 CABERNET
2013
494 A higher proportion of the treatment group had serious ocular adverse
event (54%) compared to the control group (18%). The majority of these
adverse events were cataract. Overall 5% of the treatment group had de-
vice-related adverse events (17 cases); 10 of these cases were radiation
retinopathy.
6 Char 1999 27 No comment on adverse effects in the report
7 Ciulla 2002 37 No comment on adverse effects in the report
8 Eter 2002 45 No comment on adverse effects in the report
9 INTREPID 2013 230 AEs similar across study arms and none attributed to radiation.
10 Jaakkola 2005 88 No comment on adverse effects in the report
11 Kacperek 2001 58 No comment on adverse effects in the report
12 Kobayashi 2000 101 Reported no radiation-associated adverse effects.
2 participants in treatment group "complained of transient conjunctival in-
jection that resolved within 2 weeks"
Cataract observed in 1 participant in treatment group but otherwise no evi-
dence of cataract progression.
13 Marcus 2001 83 Reported no radiation-associated adverse effects. Cataract progression sim-
ilar to treatment and control. 1 case of retinal detachment and 1 case of vit-
reous haemorrhage seen in radiation group
14 MERLOT 2016 363 In the radiotherapy plus ranibizumab group (n=244) there were 4 cases of
reduced visual acuity, 1 vitreous haemorrhage, 3 retinal haemorrhage, 3
retinal detachment, 1 vision blurred, 1 endophthalmitis, 1 vitreous floaters,
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2 postoperative uveitis. In the ranibizumab only group (n=119) there was 1
case of reduced visual acuity and 1 case of retinal haemorrhage. 
15 Osmanovic
2017
30 Reported no cases of:
• severe vision loss• adverse arteriothromboembolic events• radiation retinopathy, neuropathy or anterior segment adverse effects.
Cataract progression: Among the 13 phakic eyes (13 people) who completed
the 12-month study follow-up, 4 had cataract progression (1 control, 2 from
16 GyE, 1 from 24 GyE). One eye receiving 16 GyE PBT
underwent cataract extraction within the 1-year follow-up; however,
this individual had moderately advanced cataract
at baseline.
16 RAD 1999 205 Reported no radiation-associated adverse effects. Cataract developed in 7
(10.3%) radiation group, 12 (16%) control group) (P = 0.218). Dry eye symp-
toms in were recorded in 30 (40%) radiation group and 38 (45.2%) in control
group (P = 0.525).4 deaths unrelated to radiation treatment, 3 in radiation
group, 1 in control group
17 SFRADS 2002 203 Reported no radiation-associated adverse effects but "transient disturbance
of the precorneal tear film" was noted in treated patients"
18 Valmaggia 2002 161 Reported no radiation-associated adverse effects.
Table 6.   Adverse outcomes  (Continued)
 
 
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Macular Degeneration
#2 MeSH descriptor Retinal Degeneration
#3 MeSH descriptor Neovascularization, Pathologic
#4 (macula* near degenerat*)
#5 (macula* near neovasc*)
#6 (retina* near degener*)
#7 (retina* near neovasc*)
#8 (choroid* near degener*)
#9 (choroid* near neovasc*)
#10 (maculopath*)
#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)
#12 MeSH descriptor Radiotherapy
#13 (radiotherap* or radiat* or irradiat*)
#14 (teletherap* or tele-therap* or proton* or plaque)
#15 (external near beam)
#16 (external-beam)
#17 (#12 OR #13 OR #14 OR #15 OR #16)
#18 (#11 AND #17)
Appendix 2. MEDLINE Ovid search strategy
1 randomized controlled trial.pt.
2 (randomized or randomised).ab,ti.
3 placebo.ab,ti.
4 dt.fs.
5 randomly.ab,ti.
Radiotherapy for neovascular age-related macular degeneration (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
86
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
6 trial.ab,ti.
7 groups.ab,ti.
8 or/1-7
9 exp animals/
10 exp humans/
11 9 not (9 and 10)
12 8 not 11
13 exp macular degeneration/
14 exp retinal degeneration/
15 exp retinal neovascularization/
16 exp choroidal neovascularization/
17 exp macula lutea/
18 (macula$ adj2 lutea).tw.
19 maculopath$.tw.
20 ((macul$ or retina$ or choroid$) adj3 degener$).tw.
21 ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
22 or/13-21
23 exp radiotherapy/
24 (radiotherap$ or radiat$ or irradiat$ or teletherap$ or proton$ or plaque).tw.
25 (external adj3 beam).tw.
26 or/23-25
27 22 and 26
28 12 and 27
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase Ovid search strategy
1 exp randomized controlled trial/
2 exp randomization/
3 exp double blind procedure/
4 exp single blind procedure/
5 random$.tw.
6 or/1-5
7 (animal or animal experiment).sh.
8 human.sh.
9 7 and 8
10 7 not 9
11 6 not 10
12 exp clinical trial/
13 (clin$ adj3 trial$).tw.
14 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15 exp placebo/
16 placebo$.tw.
17 random$.tw.
18 exp experimental design/
19 exp crossover procedure/
20 exp control group/
21 exp latin square design/
22 or/12-21
23 22 not 10
24 23 not 11
25 exp comparative study/
26 exp evaluation/
27 exp prospective study/
28 (control$ or propspectiv$ or volunteer$).tw.
29 or/25-28
30 29 not 10
31 30 not (11 or 23)
32 11 or 24 or 31
33 exp retina macula age related degeneration/
34 exp retina degeneration/
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35 exp neovascularization pathology/
36 ((macul$ or retina$ or choroid$) adj3 degener$).tw.
37 ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
38 maculopath$.tw.
39 or/33-38
40 exp radiotherapy/
41 (radiotherap$ or radiat$ or irradiat$ or teletherap$ or proton$ or plaque).tw.
42 (external adj3 beam).tw.
43 or/40-42
44 39 and 43
45 32 and 44
Appendix 4. LILACS search strategy
macula$ or retina$ or choroid$ and degenerat$ or neovasc$ and radiotherap$ or radiat$ or irradiat$ or teletherap$ or proton$ or plaque
Appendix 5. ISRCTN search strategy
(Macular Degeneration OR AMD OR nAMD OR ARMD) AND (radiotherapy OR radiation OR irradiation OR teletherapy OR proton OR plaque)
Appendix 6. ClinicalTrials.gov search strategy
(Macular Degeneration OR AMD OR nAMD OR ARMD) AND (radiotherapy OR radiation OR irradiation OR teletherapy OR proton OR plaque)
Appendix 7. WHO ICTRP search strategy
macular degeneration = Condition AND radiotherapy = Intervention
W H A T ' S   N E W
 
Date Event Description
1 May 2020 New citation required and conclusions
have changed
Issue 8 2020: Four new studies included in update (CABERNET
2013; INTREPID 2013; MERLOT 2016; Osmanovic 2017)
1 May 2020 New search has been performed Issue 8 2020: Electronic searches updated
 
H I S T O R Y
Protocol first published: Issue 1, 2003
Review first published: Issue 4, 2004
 
Date Event Description
31 March 2010 New search has been performed Issue 5 2010: Updated searches yielded 3 new trials.
31 March 2010 New citation required but conclusions
have not changed
Review substantially updated including new assessment of risk
of bias and preparation of summary of findings tables.
17 March 2008 Amended Converted to new review format.
 
C O N T R I B U T I O N S   O F   A U T H O R S
Conceiving the review: VC
Designing the review, writing the protocol: VC
Co-ordinating the review: VC, JE
Data collection for the review: JE, CI
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Screening search results: JE, EP
Organising retrieval of papers: JE
Screening retrieved papers against inclusion criteria: JE, EP
Appraising quality of papers: JE, CI
Abstracting data from papers: JE, CI
Writing to authors of papers for additional information: VC, JE
Obtaining and screening data on unpublished studies: JE
Data management for the review: JE
Entering data into RevMan: JE
Analysis of data: JE
Interpretation of data: All authors
Providing a clinical perspective: VC, TJ, EP
Writing the review: JE, VC, TJ, EP
Guarantor for the review: JE
D E C L A R A T I O N S   O F   I N T E R E S T
JE: none known
CI: none known
TJ was a principal investigator and/or lead author in the CABERNET, MERLOT, MERITAGE and INTREPID studies. He leads an NIHR funded
trial of the Oraya device. His employer received research payments for participants enrolled in commercial clinical trials of radiation devices
used to treat wet AMD, and research grants or free use of radiation devices for investigator-initiated clinical trials of wet AMD.   He is a
consultant to Opthea and iLumens.
VC is consultant of Quantel Medical and is an employee of Boehringer Ingelheim. This publication expresses the opinion of the author (VC)
and is not endorsed by Boehringer Ingelheim.
S O U R C E S   O F   S U P P O R T
Internal sources• No sources of support supplied
External sources• Guide Dogs for the Blind Association, UK• National Institute for Health Research (NIHR), UK
* Richard Wormald, Co-ordinating Editor for Cochrane Eyes and Vision (CEV) received financial support for his CEV research sessions
(during this update) from the Department of Health through the award made by the National Institute for Health Research to
Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for
Ophthalmology.* This review update was supported by the NIHR, via Cochrane Infrastructure funding to the CEV UK editorial base.
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews
Programme, NIHR, NHS or the Department of Health.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
The review has been substantially updated since the original protocol was written and new methods, such assessment of risk of bias,
GRADE assessment and summary of findings table, have been incorporated.
In previous versions of this review we considered loss of 3 and 6 lines of visual acuity. We felt that loss of 6 or more lines of visual acuity
was not such a relevant outcomes now with the advent of anti-VEGF treatments and therefore made the decision to drop this outcome in
the current review update. We have included change in best-corrected visual acuity instead.
Recent trials have considered the combination of anti-VEGF and radiotherapy. As a result, we have added in a new comparison
"Radiotherapy combined with anti-VEGF versus anti-VEGF alone" and one additional outcome "number of injections of anti-VEGF". We have
considered this as an outcome because one of the potential aims of radiotherapy would be to reduce the number of anti-VEGF injections
required.
We also dropped the 6 month follow-up period and have focused on 12 and 24 months only.
In previous version of this review (Evans 2010) we assessed the potential impact of missing data in some detail and assessed the potential
for selective outcome reporting using the ORBIT classification (Kirkham 2010). As these analyses did not point to any major sources of bias
we have not updated them for the current version of this review.
Radiotherapy for neovascular age-related macular degeneration (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
89
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Eye  [radiation eEects];  Macular Degeneration  [*radiotherapy];  Radiation Injuries  [complications];  Randomized Controlled Trials as
Topic
MeSH check words
Humans
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